-
1
-
-
79952384705
-
Cancer epigenetics reaches mainstream oncology
-
Rodríguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17(3):330–339
-
(2011)
Nat Med
, vol.17
, Issue.3
, pp. 330-339
-
-
Rodríguez-Paredes, M.1
Esteller, M.2
-
3
-
-
32844459336
-
The Polycomb group protein EZH2 directly controls DNA methylation
-
Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden J-M, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078):871–874
-
(2006)
Nature
, vol.439
, Issue.7078
, pp. 871-874
-
-
Viré, E.1
Brenner, C.2
Deplus, R.3
Blanchon, L.4
Fraga, M.5
Didelot, C.6
Morey, L.7
Van Eynde, A.8
Bernard, D.9
Vanderwinden, J.-M.10
Bollen, M.11
Esteller, M.12
Di Croce, L.13
de Launoit, Y.14
Fuks, F.15
-
4
-
-
0036144048
-
DNA methylation patterns and epigenetic memory
-
COI: 1:CAS:528:DC%2BD38Xos1ehsQ%3D%3D
-
Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16(1):6–21
-
(2002)
Genes Dev
, vol.16
, Issue.1
, pp. 6-21
-
-
Bird, A.1
-
5
-
-
79251566746
-
Physical and functional HAT/HDAC interplay regulates protein acetylation balance
-
Peserico A, Simone C (2011) Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol. doi:10.1155/2011/371832
-
(2011)
J Biomed Biotechnol
-
-
Peserico, A.1
Simone, C.2
-
6
-
-
77954879663
-
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma
-
COI: 1:CAS:528:DC%2BC3cXhsVejt7zL
-
Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28(29):4485–4491
-
(2010)
J Clin Oncol
, vol.28
, Issue.29
, pp. 4485-4491
-
-
Whittaker, S.J.1
Demierre, M.F.2
Kim, E.J.3
Rook, A.H.4
Lerner, A.5
Duvic, M.6
Scarisbrick, J.7
Reddy, S.8
Robak, T.9
Becker, J.C.10
Samtsov, A.11
McCulloch, W.12
Kim, Y.H.13
-
7
-
-
84885859135
-
Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents
-
Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G (2013) Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol 88(2):231–245
-
(2013)
Crit Rev Oncol Hematol
, vol.88
, Issue.2
, pp. 231-245
-
-
Santini, V.1
Melnick, A.2
Maciejewski, J.P.3
Duprez, E.4
Nervi, C.5
Cocco, L.6
Ford, K.G.7
Mufti, G.8
-
8
-
-
84949908674
-
Epigenetic treatment of solid tumours: a review of clinical trials
-
Nervi C, De Marinis E, Codacci-Pisanelli G (2015) Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenet 7(1):127
-
(2015)
Clin Epigenet
, vol.7
, Issue.1
, pp. 127
-
-
Nervi, C.1
De Marinis, E.2
Codacci-Pisanelli, G.3
-
9
-
-
0036488643
-
Natural products in cancer chemotherapy: past, present and future
-
COI: 1:CAS:528:DC%2BD38XitVehtL8%3D
-
Mann J (2002) Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2(2):143–148
-
(2002)
Nat Rev Cancer
, vol.2
, Issue.2
, pp. 143-148
-
-
Mann, J.1
-
11
-
-
84879095158
-
Perspectives on natural product epigenetic modulators in chemical biology and medicine
-
COI: 1:CAS:528:DC%2BC3sXmtVWqs7s%3D
-
Cherblanc FL, Davidson RWM, Di Fruscia P, Srimongkolpithak N, Fuchter MJ (2013) Perspectives on natural product epigenetic modulators in chemical biology and medicine. Nat Prod Rep 30(5):605
-
(2013)
Nat Prod Rep
, vol.30
, Issue.5
, pp. 605
-
-
Cherblanc, F.L.1
Davidson, R.W.M.2
Di Fruscia, P.3
Srimongkolpithak, N.4
Fuchter, M.J.5
-
12
-
-
33645987615
-
Epigenetic control using natural products and synthetic molecules
-
COI: 1:CAS:528:DC%2BD28Xislygsbo%3D
-
Suzuki T, Miyata N (2006) Epigenetic control using natural products and synthetic molecules. Curr Med Chem 13(8):935–958
-
(2006)
Curr Med Chem
, vol.13
, Issue.8
, pp. 935-958
-
-
Suzuki, T.1
Miyata, N.2
-
13
-
-
0345357773
-
Gene silencing in cancer in association with promoter hypermethylation
-
COI: 1:CAS:528:DC%2BD3sXptFKmu7s%3D
-
Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042–2054
-
(2003)
N Engl J Med
, vol.349
, Issue.21
, pp. 2042-2054
-
-
Herman, J.G.1
Baylin, S.B.2
-
14
-
-
33947315736
-
Cancer epigenomics: DNA methylomes and histone-modification maps
-
COI: 1:CAS:528:DC%2BD2sXivVGktbk%3D
-
Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8(4):286–298
-
(2007)
Nat Rev Genet
, vol.8
, Issue.4
, pp. 286-298
-
-
Esteller, M.1
-
15
-
-
0031469819
-
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
-
COI: 1:CAS:528:DyaK2sXns12rsL8%3D
-
Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404–407
-
(1997)
Nature
, vol.390
, Issue.6658
, pp. 404-407
-
-
Boehm, T.1
Folkman, J.2
Browder, T.3
O’Reilly, M.S.4
-
16
-
-
0034090097
-
Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
-
COI: 1:CAS:528:DC%2BD3cXks1SksLw%3D
-
Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52(2):237–268
-
(2000)
Pharmacol Rev
, vol.52
, Issue.2
, pp. 237-268
-
-
Griffioen, A.W.1
Molema, G.2
-
17
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
COI: 1:CAS:528:DC%2BD1cXovV2lsrk%3D
-
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592–603
-
(2008)
Nat Rev Cancer
, vol.8
, Issue.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
18
-
-
84931271695
-
The great escape; the hallmarks of resistance to antiangiogenic therapy
-
van Beijnum JR, Nowak-Sliwinska P, Huijbers EJM, Thijssen VL, Griffioen AW (2015) The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev 67(2):441–461
-
(2015)
Pharmacol Rev
, vol.67
, Issue.2
, pp. 441-461
-
-
van Beijnum, J.R.1
Nowak-Sliwinska, P.2
Huijbers, E.J.M.3
Thijssen, V.L.4
Griffioen, A.W.5
-
19
-
-
84960431096
-
Role of the tumor stroma in resistance to anti-angiogenic therapy
-
Huijbers EJM, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW (2016) Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updates 25:26–37
-
(2016)
Drug Resist Updates
, vol.25
, pp. 26-37
-
-
Huijbers, E.J.M.1
van Beijnum, J.R.2
Thijssen, V.L.3
Sabrkhany, S.4
Nowak-Sliwinska, P.5
Griffioen, A.W.6
-
20
-
-
85017106819
-
Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists
-
Bani MR, Decio A, Giavazzi R, Ghilardi C (2017) Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. Angiogenesis. doi:10.1007/s10456-017-9549-6
-
(2017)
Angiogenesis
-
-
Bani, M.R.1
Decio, A.2
Giavazzi, R.3
Ghilardi, C.4
-
21
-
-
84930868061
-
Histone deacetylase inhibitors in hematological malignancies and solid tumors
-
COI: 1:CAS:528:DC%2BC2MXit1aqu7g%3D
-
Chun P (2015) Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 38(6):933–949
-
(2015)
Arch Pharm Res
, vol.38
, Issue.6
, pp. 933-949
-
-
Chun, P.1
-
22
-
-
34249323034
-
Identification of epigenetically silenced genes in tumor endothelial cells
-
COI: 1:CAS:528:DC%2BD2sXltVyrsrs%3D
-
Hellebrekers DMEI, Melotte V, Viré E, Langenkamp E, Molema G, Fuks F, Herman JG, Van Criekinge W, Griffioen AW, Van Engeland M (2007) Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67(9):4138–4148
-
(2007)
Cancer Res
, vol.67
, Issue.9
, pp. 4138-4148
-
-
Hellebrekers, D.M.E.I.1
Melotte, V.2
Viré, E.3
Langenkamp, E.4
Molema, G.5
Fuks, F.6
Herman, J.G.7
Van Criekinge, W.8
Griffioen, A.W.9
Van Engeland, M.10
-
23
-
-
0030916336
-
What’s up and down with histone deacetylation and transcription?
-
COI: 1:CAS:528:DyaK2sXjtFWisLY%3D
-
Pazin MJ, Kadonaga JT (1997) What’s up and down with histone deacetylation and transcription? Cell 89(3):325–328
-
(1997)
Cell
, vol.89
, Issue.3
, pp. 325-328
-
-
Pazin, M.J.1
Kadonaga, J.T.2
-
24
-
-
0030797585
-
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
-
COI: 1:CAS:528:DyaK2sXlvFKmtLc%3D
-
Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90(4):595–606
-
(1997)
Cell
, vol.90
, Issue.4
, pp. 595-606
-
-
Gu, W.1
Roeder, R.G.2
-
25
-
-
0032544123
-
Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases
-
COI: 1:CAS:528:DyaK1cXlsFSrt7g%3D
-
Zhang W, Bieker JJ (1998) Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci USA 95(17):9855–9860
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, Issue.17
, pp. 9855-9860
-
-
Zhang, W.1
Bieker, J.J.2
-
26
-
-
36048958965
-
Histone deacetylase inhibitors: overview and perspectives
-
COI: 1:CAS:528:DC%2BD2sXhtFygsLvN
-
Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5(10):981–989
-
(2007)
Mol Cancer Res
, vol.5
, Issue.10
, pp. 981-989
-
-
Dokmanovic, M.1
Clarke, C.2
Marks, P.A.3
-
27
-
-
37349089053
-
Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis
-
COI: 1:CAS:528:DC%2BD2sXhtlOjsL3N
-
Mottet D, Bellahcène A, Pirotte S, Waltregny D, Deroanne C, Lamour V, Lidereau R, Castronovo V (2007) Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res 101(12):1237–1246
-
(2007)
Circ Res
, vol.101
, Issue.12
, pp. 1237-1246
-
-
Mottet, D.1
Bellahcène, A.2
Pirotte, S.3
Waltregny, D.4
Deroanne, C.5
Lamour, V.6
Lidereau, R.7
Castronovo, V.8
-
28
-
-
33947313218
-
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
-
COI: 1:CAS:528:DC%2BD2sXivVSmur0%3D
-
Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C (2007) HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17(3):195–211
-
(2007)
Cell Res
, vol.17
, Issue.3
, pp. 195-211
-
-
Gallinari, P.1
Di Marco, S.2
Jones, P.3
Pallaoro, M.4
Steinkühler, C.5
-
29
-
-
33744963443
-
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha
-
COI: 1:CAS:528:DC%2BD28Xkt1ymtLg%3D
-
Fath DM, Kong X, Liang D, Lin Z, Chou A, Jiang Y, Fang J, Caro J, Sang N (2006) Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem 281(19):13612–13619
-
(2006)
J Biol Chem
, vol.281
, Issue.19
, pp. 13612-13619
-
-
Fath, D.M.1
Kong, X.2
Liang, D.3
Lin, Z.4
Chou, A.5
Jiang, Y.6
Fang, J.7
Caro, J.8
Sang, N.9
-
30
-
-
76349095132
-
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
-
COI: 1:CAS:528:DC%2BD1MXhsV2gt77N
-
Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29(5):625–634
-
(2010)
Oncogene
, vol.29
, Issue.5
, pp. 625-634
-
-
Semenza, G.L.1
-
31
-
-
50349091316
-
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors
-
COI: 1:CAS:528:DC%2BD1cXmslygt7s%3D
-
Verheul HMW, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14(11):3589–3597
-
(2008)
Clin Cancer Res
, vol.14
, Issue.11
, pp. 3589-3597
-
-
Verheul, H.M.W.1
Salumbides, B.2
Van Erp, K.3
Hammers, H.4
Qian, D.Z.5
Sanni, T.6
Atadja, P.7
Pili, R.8
-
32
-
-
0038544192
-
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents
-
COI: 1:CAS:528:DC%2BD3sXhtV2isbk%3D
-
Kim DH, Kim M, Kwon HJ (2003) Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36(1):110–119
-
(2003)
J Biochem Mol Biol
, vol.36
, Issue.1
, pp. 110-119
-
-
Kim, D.H.1
Kim, M.2
Kwon, H.J.3
-
33
-
-
0035048449
-
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
-
Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SWK, Moon EJ, Kim HS, Lee SWK, Chung HY, Kim CW, Kim KW (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4):437–443
-
(2001)
Nat Med
, vol.7
, Issue.4
, pp. 437-443
-
-
Kim, M.S.1
Kwon, H.J.2
Lee, Y.M.3
Baek, J.H.4
Jang, J.E.5
Lee, S.W.K.6
Moon, E.J.7
Kim, H.S.8
Lee, S.W.K.9
Chung, H.Y.10
Kim, C.W.11
Kim, K.W.12
-
34
-
-
16644379041
-
Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo
-
COI: 1:CAS:528:DC%2BD2MXhsVyjsA%3D%3D
-
Michaelis M, Suhan T, Cinatl J, Driever PH, Cinatl J (2004) Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25(6):1795–1799
-
(2004)
Int J Oncol
, vol.25
, Issue.6
, pp. 1795-1799
-
-
Michaelis, M.1
Suhan, T.2
Cinatl, J.3
Driever, P.H.4
Cinatl, J.5
-
35
-
-
10744226890
-
Valproic acid inhibits angiogenesis in vitro and in vivo
-
COI: 1:CAS:528:DC%2BD2cXhs1Kgt7s%3D
-
Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl JJ, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H, Cinatl JJ (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65(3):520–527
-
(2004)
Mol Pharmacol
, vol.65
, Issue.3
, pp. 520-527
-
-
Michaelis, M.1
Michaelis, U.R.2
Fleming, I.3
Suhan, T.4
Cinatl, J.J.5
Blaheta, R.A.6
Hoffmann, K.7
Kotchetkov, R.8
Busse, R.9
Nau, H.10
Cinatl, J.J.11
-
36
-
-
67349201377
-
Targeting tumor angiogenesis with histone deacetylase inhibitors
-
COI: 1:CAS:528:DC%2BD1MXmsF2jt74%3D
-
Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280(2):145–153
-
(2009)
Cancer Lett
, vol.280
, Issue.2
, pp. 145-153
-
-
Ellis, L.1
Hammers, H.2
Pili, R.3
-
37
-
-
33644780111
-
Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1α
-
COI: 1:CAS:528:DC%2BD28Xislygt70%3D
-
Kong X, Lin Z, Liang D, Fath D (2006) Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1α. Mol Cell Biol 26(6):2019–2028
-
(2006)
Mol Cell Biol
, vol.26
, Issue.6
, pp. 2019-2028
-
-
Kong, X.1
Lin, Z.2
Liang, D.3
Fath, D.4
-
38
-
-
33845310374
-
Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications
-
COI: 1:CAS:528:DC%2BD2sXivVyqsLg%3D
-
Hellebrekers DMEI et al (2006) Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 66(22):10770–10777
-
(2006)
Cancer Res
, vol.66
, Issue.22
, pp. 10770-10777
-
-
Hellebrekers, D.M.E.I.1
-
39
-
-
78650443648
-
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo
-
COI: 1:CAS:528:DC%2BC3cXhsFGrsLzE
-
Srivastava RK, Kurzrock R, Shankar S (2010) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 9(12):3254–3266
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.12
, pp. 3254-3266
-
-
Srivastava, R.K.1
Kurzrock, R.2
Shankar, S.3
-
40
-
-
0037225763
-
Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity
-
Mie Lee Y, Kim S-H, Kim H-S, Jin Son M, Nakajima H, Jeong Kwon H, Kim K-W (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300(1):241–246
-
(2003)
Biochem Biophys Res Commun
, vol.300
, Issue.1
, pp. 241-246
-
-
Mie Lee, Y.1
Kim, S.-H.2
Kim, H.-S.3
Jin Son, M.4
Nakajima, H.5
Jeong Kwon, H.6
Kim, K.-W.7
-
41
-
-
84919372520
-
New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours
-
COI: 1:CAS:528:DC%2BC2cXitFSqt7bL
-
Vieira-Coimbra M, Henrique R, Jeronimo C (2015) New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours. Eur J Clin Invest 45:16–24
-
(2015)
Eur J Clin Invest
, vol.45
, pp. 16-24
-
-
Vieira-Coimbra, M.1
Henrique, R.2
Jeronimo, C.3
-
42
-
-
33746228132
-
Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10
-
COI: 1:CAS:528:DC%2BD28Xot1OntL8%3D
-
Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126(2):321–334
-
(2006)
Cell
, vol.126
, Issue.2
, pp. 321-334
-
-
Chang, S.1
Young, B.D.2
Li, S.3
Qi, X.4
Richardson, J.A.5
Olson, E.N.6
-
43
-
-
4744368147
-
Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity
-
COI: 1:CAS:528:DC%2BD2cXnvFWnsL0%3D
-
Kato H, Tamamizu-Kato S, Shibasaki F (2004) Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 279(40):41966–41974
-
(2004)
J Biol Chem
, vol.279
, Issue.40
, pp. 41966-41974
-
-
Kato, H.1
Tamamizu-Kato, S.2
Shibasaki, F.3
-
44
-
-
84874380158
-
Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells
-
COI: 1:CAS:528:DC%2BC3sXisVKqt7Y%3D
-
Kaluza D, Kroll J, Gesierich S, Manavski Y, Boeckel J-N, Doebele C, Zelent A, Rossig L, Zeiher AM, Augustin HG, Urbich C, Dimmeler S (2013) Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. Arterioscler Thromb Vasc Biol 33(3):533–543
-
(2013)
Arterioscler Thromb Vasc Biol
, vol.33
, Issue.3
, pp. 533-543
-
-
Kaluza, D.1
Kroll, J.2
Gesierich, S.3
Manavski, Y.4
Boeckel, J.-N.5
Doebele, C.6
Zelent, A.7
Rossig, L.8
Zeiher, A.M.9
Augustin, H.G.10
Urbich, C.11
Dimmeler, S.12
-
45
-
-
80054881600
-
Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin
-
COI: 1:CAS:528:DC%2BC3MXhtVWrtLzK
-
Kaluza D, Kroll J, Gesierich S, Yao T-P, Boon RA, Hergenreider E, Tjwa M, Rossig L, Seto E, Augustin HG, Zeiher AM, Dimmeler S, Urbich C (2011) Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin. EMBO J 30(20):4142–4156
-
(2011)
EMBO J
, vol.30
, Issue.20
, pp. 4142-4156
-
-
Kaluza, D.1
Kroll, J.2
Gesierich, S.3
Yao, T.-P.4
Boon, R.A.5
Hergenreider, E.6
Tjwa, M.7
Rossig, L.8
Seto, E.9
Augustin, H.G.10
Zeiher, A.M.11
Dimmeler, S.12
Urbich, C.13
-
46
-
-
85010866733
-
Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism
-
COI: 1:CAS:528:DC%2BC2sXhs1Gis7s%3D
-
Hrgovic I, Doll M, Pinter A, Kaufmann R, Kippenberger S, Meissner M (2017) Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism. Exp Dermatol 26(2):194–201
-
(2017)
Exp Dermatol
, vol.26
, Issue.2
, pp. 194-201
-
-
Hrgovic, I.1
Doll, M.2
Pinter, A.3
Kaufmann, R.4
Kippenberger, S.5
Meissner, M.6
-
47
-
-
4644224489
-
VE-cadherin increases the half-life of VEGF receptor 2
-
COI: 1:CAS:528:DC%2BD2cXnslKrsL0%3D
-
Calera MR, Venkatakrishnan A, Kazlauskas A (2004) VE-cadherin increases the half-life of VEGF receptor 2. Exp Cell Res 300(1):248–256
-
(2004)
Exp Cell Res
, vol.300
, Issue.1
, pp. 248-256
-
-
Calera, M.R.1
Venkatakrishnan, A.2
Kazlauskas, A.3
-
48
-
-
84978180058
-
Trichostatin A, a histone deacetylase inhibitor suppresses NADPH Oxidase 4-Derived Redox Signalling and Angiogenesis
-
COI: 1:CAS:528:DC%2BC28XhsV2ksb3F
-
Hakami NY, Dusting GJ, Peshavariya HM (2016) Trichostatin A, a histone deacetylase inhibitor suppresses NADPH Oxidase 4-Derived Redox Signalling and Angiogenesis. J Cell Mol Med 20(10):1932–1944
-
(2016)
J Cell Mol Med
, vol.20
, Issue.10
, pp. 1932-1944
-
-
Hakami, N.Y.1
Dusting, G.J.2
Peshavariya, H.M.3
-
49
-
-
85047699941
-
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
-
COI: 1:CAS:528:DC%2BD38XhtVygtL4%3D
-
Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart J-M, Nusgens BV, Castronovo V (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3):427–436
-
(2002)
Oncogene
, vol.21
, Issue.3
, pp. 427-436
-
-
Deroanne, C.F.1
Bonjean, K.2
Servotte, S.3
Devy, L.4
Colige, A.5
Clausse, N.6
Blacher, S.7
Verdin, E.8
Foidart, J.-M.9
Nusgens, B.V.10
Castronovo, V.11
-
50
-
-
4644364508
-
The histone deacetylase inhibitor NVP-LAQ824 Inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584
-
COI: 1:CAS:528:DC%2BD2cXnsFOlu7w%3D
-
Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R (2004) The histone deacetylase inhibitor NVP-LAQ824 Inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64(18):6626–6634
-
(2004)
Cancer Res
, vol.64
, Issue.18
, pp. 6626-6634
-
-
Qian, D.Z.1
Wang, X.2
Kachhap, S.K.3
Kato, Y.4
Wei, Y.5
Zhang, L.6
Atadja, P.7
Pili, R.8
-
51
-
-
47849088748
-
Emerging roles of SIRT1 in vascular endothelial homeostasis
-
COI: 1:CAS:528:DC%2BD1cXhtVykurzK
-
Potente M, Dimmeler S (2008) Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 7(14):2117–2122
-
(2008)
Cell Cycle
, vol.7
, Issue.14
, pp. 2117-2122
-
-
Potente, M.1
Dimmeler, S.2
-
52
-
-
34547875773
-
Sirtuins: critical regulators at the crossroads between cancer and aging
-
COI: 1:CAS:528:DC%2BD2sXovFersro%3D
-
Saunders LR, Verdin E (2007) Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26(37):5489–5504
-
(2007)
Oncogene
, vol.26
, Issue.37
, pp. 5489-5504
-
-
Saunders, L.R.1
Verdin, E.2
-
53
-
-
84870203841
-
Anti-inflammatory properties of sirtuin 6 in human umbilical vein endothelial cells
-
Lappas M (2012) Anti-inflammatory properties of sirtuin 6 in human umbilical vein endothelial cells. Mediat Inflamm 2012:597514
-
(2012)
Mediat Inflamm
, vol.2012
, pp. 597514
-
-
Lappas, M.1
-
54
-
-
54149103338
-
Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice
-
COI: 1:CAS:528:DC%2BD1cXht1Knt7jI
-
Zhang Q-J, Wang Z, Chen H-Z, Zhou S, Zheng W, Liu G, Wei Y-S, Cai H, Liu D-P, Liang C-C (2008) Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 80(2):191–199
-
(2008)
Cardiovasc Res
, vol.80
, Issue.2
, pp. 191-199
-
-
Zhang, Q.-J.1
Wang, Z.2
Chen, H.-Z.3
Zhou, S.4
Zheng, W.5
Liu, G.6
Wei, Y.-S.7
Cai, H.8
Liu, D.-P.9
Liang, C.-C.10
-
55
-
-
84994026397
-
Natural products as mechanism-based anticancer agents: Sp transcription factors as targets
-
COI: 1:CAS:528:DC%2BC28XhslOqurvO
-
Safe S, Kasiappan R (2016) Natural products as mechanism-based anticancer agents: Sp transcription factors as targets. Phyther Res 30(11):1723–1732
-
(2016)
Phyther Res
, vol.30
, Issue.11
, pp. 1723-1732
-
-
Safe, S.1
Kasiappan, R.2
-
56
-
-
84874459800
-
Cancer chemoprevention and nutri-epigenetics: state of the art and future challenges
-
Gerhauser C (2013) Cancer chemoprevention and nutri-epigenetics: state of the art and future challenges. Top Curr Chem 11(1):73–132
-
(2013)
Top Curr Chem
, vol.11
, Issue.1
, pp. 73-132
-
-
Gerhauser, C.1
-
57
-
-
51649092812
-
Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—part 2
-
COI: 1:STN:280:DC%2BD2szmt1Whtg%3D%3D
-
Sagar SM, Yance D, Wong RK (2006) Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—part 2. Curr Oncol 13(3):14–26
-
(2006)
Curr Oncol
, vol.13
, Issue.3
, pp. 14-26
-
-
Sagar, S.M.1
Yance, D.2
Wong, R.K.3
-
58
-
-
84913582432
-
Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer
-
COI: 1:CAS:528:DC%2BC2cXhvFCns7%2FF
-
Dhar S, Kumar A, Li K, Tzivion G, Levenson AS (2015) Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer. Biochim Biophys Acta Mol Cell Res 1853(2):265–275
-
(2015)
Biochim Biophys Acta Mol Cell Res
, vol.1853
, Issue.2
, pp. 265-275
-
-
Dhar, S.1
Kumar, A.2
Li, K.3
Tzivion, G.4
Levenson, A.S.5
-
59
-
-
84984706653
-
Cytotoxic effects of peanut phenolics possessing histone deacetylase inhibitory activity in breast and cervical cancer cell lines
-
COI: 1:CAS:528:DC%2BC28XhsVelt7vL
-
Saenglee S, Jogloy S, Patanothai A, Leid M, Senawong T (2016) Cytotoxic effects of peanut phenolics possessing histone deacetylase inhibitory activity in breast and cervical cancer cell lines. Pharmacol Rep 68(6):1102–1110
-
(2016)
Pharmacol Rep
, vol.68
, Issue.6
, pp. 1102-1110
-
-
Saenglee, S.1
Jogloy, S.2
Patanothai, A.3
Leid, M.4
Senawong, T.5
-
60
-
-
1642382931
-
Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats
-
COI: 1:CAS:528:DC%2BD2cXisVGks7k%3D
-
Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, Chen CK, Lin PY, Chen Y (2004) Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 10(6):2190–2202
-
(2004)
Clin Cancer Res
, vol.10
, Issue.6
, pp. 2190-2202
-
-
Tseng, S.H.1
Lin, S.M.2
Chen, J.C.3
Su, Y.H.4
Huang, H.Y.5
Chen, C.K.6
Lin, P.Y.7
Chen, Y.8
-
61
-
-
85007487828
-
Silibinin and colorectal cancer chemoprevention: a comprehensive review on mechanisms and efficacy
-
Raina K, Kumar S, Dhar D, Agarwal R (2016) Silibinin and colorectal cancer chemoprevention: a comprehensive review on mechanisms and efficacy. J Biomed Res 30(6):452–465
-
(2016)
J Biomed Res
, vol.30
, Issue.6
, pp. 452-465
-
-
Raina, K.1
Kumar, S.2
Dhar, D.3
Agarwal, R.4
-
62
-
-
84986004286
-
Silibinin inhibits hypoxia-induced HIF-1α–mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: in vitro evidence and in vivo functional imaging and metabolomics
-
Deep G, Kumar R, Nambiar DK, Jain AK, Ramteke AM, Serkova NJ, Agarwal C, Agarwal R (2016) Silibinin inhibits hypoxia-induced HIF-1α–mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: in vitro evidence and in vivo functional imaging and metabolomics. Mol Carcinog 56(3):833–848
-
(2016)
Mol Carcinog
, vol.56
, Issue.3
, pp. 833-848
-
-
Deep, G.1
Kumar, R.2
Nambiar, D.K.3
Jain, A.K.4
Ramteke, A.M.5
Serkova, N.J.6
Agarwal, C.7
Agarwal, R.8
-
63
-
-
0034675269
-
Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells
-
COI: 1:CAS:528:DC%2BD3cXmslKnurk%3D
-
Jiang C, Agarwal R, Lü J (2000) Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochem Biophys Res Commun 276(1):371–378
-
(2000)
Biochem Biophys Res Commun
, vol.276
, Issue.1
, pp. 371-378
-
-
Jiang, C.1
Agarwal, R.2
Lü, J.3
-
64
-
-
0141786950
-
Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis
-
COI: 1:CAS:528:DC%2BD3sXnsValt7c%3D
-
Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R (2003) Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomark Prev 12(9):933–939
-
(2003)
Cancer Epidemiol Biomark Prev
, vol.12
, Issue.9
, pp. 933-939
-
-
Singh, R.P.1
Sharma, G.2
Dhanalakshmi, S.3
Agarwal, C.4
Agarwal, R.5
-
65
-
-
85006210753
-
Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression
-
Singh T, Prasad R, Katiyar SK (2016) Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression. Am J Cancer Res 6(6):1287–1301
-
(2016)
Am J Cancer Res
, vol.6
, Issue.6
, pp. 1287-1301
-
-
Singh, T.1
Prasad, R.2
Katiyar, S.K.3
-
66
-
-
0030459140
-
The role of DNA methylation in cancer genetics and epigenetics
-
COI: 1:CAS:528:DyaK2sXht12k
-
Laird PW, Jaenisch R (1996) The role of DNA methylation in cancer genetics and epigenetics. Annu Rev Genet 30(1):441–464
-
(1996)
Annu Rev Genet
, vol.30
, Issue.1
, pp. 441-464
-
-
Laird, P.W.1
Jaenisch, R.2
-
67
-
-
0024081657
-
Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter
-
COI: 1:CAS:528:DyaL1cXmt1eksLk%3D
-
Watt F, Molloy PL (1988) Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev 2(9):1136–1143
-
(1988)
Genes Dev
, vol.2
, Issue.9
, pp. 1136-1143
-
-
Watt, F.1
Molloy, P.L.2
-
68
-
-
0031792779
-
Identification and characterization of a family of mammalian methyl-CpG binding proteins
-
COI: 1:CAS:528:DyaK1cXmvF2nsrg%3D
-
Hendrich B, Bird A (1998) Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18(11):6538–6547
-
(1998)
Mol Cell Biol
, vol.18
, Issue.11
, pp. 6538-6547
-
-
Hendrich, B.1
Bird, A.2
-
69
-
-
0025975985
-
DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein
-
COI: 1:CAS:528:DyaK3MXit1amu7Y%3D
-
Boyes J, Bird A (1991) DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 64(6):1123–1134
-
(1991)
Cell
, vol.64
, Issue.6
, pp. 1123-1134
-
-
Boyes, J.1
Bird, A.2
-
70
-
-
0032574977
-
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
-
Bird A, Nan X, Ng H-H, Johnson CA, Laherty CD, Turner BM, Eisenman RN (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683):386–389
-
(1998)
Nature
, vol.393
, Issue.6683
, pp. 386-389
-
-
Bird, A.1
Nan, X.2
Ng, H.-H.3
Johnson, C.A.4
Laherty, C.D.5
Turner, B.M.6
Eisenman, R.N.7
-
71
-
-
0031860739
-
Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases
-
COI: 1:CAS:528:DyaK1cXls1Sns7w%3D
-
Okano M, Xie S, Li E (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Am Inc 19(3):219–220
-
(1998)
Nat Am Inc
, vol.19
, Issue.3
, pp. 219-220
-
-
Okano, M.1
Xie, S.2
Li, E.3
-
72
-
-
0033615717
-
DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development
-
COI: 1:CAS:528:DyaK1MXnt1Gqsrc%3D
-
Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99(3):247–257
-
(1999)
Cell
, vol.99
, Issue.3
, pp. 247-257
-
-
Okano, M.1
Bell, D.W.2
Haber, D.A.3
Li, E.4
-
73
-
-
0028786951
-
Loss of methylation activates Xist in somatic but not in embryonic cells
-
COI: 1:CAS:528:DyaK2MXos12itrY%3D
-
Beard C, Li E, Jaenisch R (1995) Loss of methylation activates Xist in somatic but not in embryonic cells. Genes Dev 9(19):2325–2334
-
(1995)
Genes Dev
, vol.9
, Issue.19
, pp. 2325-2334
-
-
Beard, C.1
Li, E.2
Jaenisch, R.3
-
74
-
-
0026697174
-
Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain
-
COI: 1:CAS:528:DyaK38XkvVGrs70%3D
-
Bestor TH (1992) Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J 11(7):2611–2617
-
(1992)
EMBO J
, vol.11
, Issue.7
, pp. 2611-2617
-
-
Bestor, T.H.1
-
75
-
-
0026708177
-
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
-
COI: 1:CAS:528:DyaK38XksVGgsr0%3D
-
Li E, Bestor TH, Jaenisch R (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69(6):915–926
-
(1992)
Cell
, vol.69
, Issue.6
, pp. 915-926
-
-
Li, E.1
Bestor, T.H.2
Jaenisch, R.3
-
76
-
-
42549126341
-
Epigenetic regulation of vascular endothelial gene expression
-
COI: 1:CAS:528:DC%2BD1cXkvVemsr0%3D
-
Matouk CC, Marsden PA (2008) Epigenetic regulation of vascular endothelial gene expression. Circ Res 102(8):873–878
-
(2008)
Circ Res
, vol.102
, Issue.8
, pp. 873-878
-
-
Matouk, C.C.1
Marsden, P.A.2
-
77
-
-
78449302346
-
DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability
-
Şahin M, Şahin E, Gümüşlü S, Erdoǧan A, Gültekin M (2010) DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability. Cancer Metastasis Rev 29(4):655–676
-
(2010)
Cancer Metastasis Rev
, vol.29
, Issue.4
, pp. 655-676
-
-
Şahin, M.1
Şahin, E.2
Gümüşlü, S.3
Erdoǧan, A.4
Gültekin, M.5
-
78
-
-
77951695444
-
Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma
-
Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z, Yang Z, Kuang G (2010) Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol. doi:10.1155/2010/721485
-
(2010)
J Biomed Biotechnol
-
-
Guo, W.1
Dong, Z.2
He, M.3
Guo, Y.4
Guo, J.5
Chen, Z.6
Yang, Z.7
Kuang, G.8
-
79
-
-
84882686726
-
Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer
-
COI: 1:CAS:528:DC%2BC3sXhs1agsb%2FF
-
Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, Zhou J, Hu J, Jiang B (2013) Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep 30(4):1976–1984
-
(2013)
Oncol Rep
, vol.30
, Issue.4
, pp. 1976-1984
-
-
Zhang, Y.1
Wang, X.2
Xu, B.3
Wang, B.4
Wang, Z.5
Liang, Y.6
Zhou, J.7
Hu, J.8
Jiang, B.9
-
80
-
-
34250310905
-
The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas
-
COI: 1:CAS:528:DC%2BD2sXms1SqsLw%3D
-
Chan SL, Cui Y, van Hasselt A, Li H, Srivastava G, Jin H, Ng KM, Wang Y, Lee KY, Tsao GSW, Zhong S, Robertson KD, Rha SY, Chan ATC, Tao Q (2007) The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Investig 87(7):644–650
-
(2007)
Lab Investig
, vol.87
, Issue.7
, pp. 644-650
-
-
Chan, S.L.1
Cui, Y.2
van Hasselt, A.3
Li, H.4
Srivastava, G.5
Jin, H.6
Ng, K.M.7
Wang, Y.8
Lee, K.Y.9
Tsao, G.S.W.10
Zhong, S.11
Robertson, K.D.12
Rha, S.Y.13
Chan, A.T.C.14
Tao, Q.15
-
81
-
-
70349656779
-
Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer
-
Bo BL, Eun JL, Eun HJ, Chun HK, Dong KC, Sang YS, Park J, Kim DH (2009) Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15(19):6185–6191
-
(2009)
Clin Cancer Res
, vol.15
, Issue.19
, pp. 6185-6191
-
-
Bo, B.L.1
Eun, J.L.2
Eun, H.J.3
Chun, H.K.4
Dong, K.C.5
Sang, Y.S.6
Park, J.7
Kim, D.H.8
-
82
-
-
68349139365
-
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer
-
Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, Dahl E (2009) Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer. doi:10.1186/1471-2407-9-217
-
(2009)
BMC Cancer
-
-
Veeck, J.1
Wild, P.J.2
Fuchs, T.3
Schüffler, P.J.4
Hartmann, A.5
Knüchel, R.6
Dahl, E.7
-
83
-
-
84893694694
-
Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation
-
COI: 1:CAS:528:DC%2BC3sXhtFGmurnI
-
Lee SM, Park JY, Kim DS (2013) Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells 36(1):69–73
-
(2013)
Mol Cells
, vol.36
, Issue.1
, pp. 69-73
-
-
Lee, S.M.1
Park, J.Y.2
Kim, D.S.3
-
84
-
-
80052773858
-
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence
-
COI: 1:CAS:528:DC%2BC3MXhtVOntL7K
-
Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME (2011) The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol 13(7):736–747
-
(2011)
Neuro Oncol
, vol.13
, Issue.7
, pp. 736-747
-
-
Lambiv, W.L.1
Vassallo, I.2
Delorenzi, M.3
Shay, T.4
Diserens, A.C.5
Misra, A.6
Feuerstein, B.7
Murat, A.8
Migliavacca, E.9
Hamou, M.F.10
Sciuscio, D.11
Burger, R.12
Domany, E.13
Stupp, R.14
Hegi, M.E.15
-
85
-
-
14044278776
-
Glycogen-synthase kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells
-
COI: 1:CAS:528:DC%2BD2MXhtF2nsLc%3D
-
Skurk C, Maatz H, Rocnik E, Bialik A, Force T, Walsh K (2005) Glycogen-synthase kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res 96(3):308–318
-
(2005)
Circ Res
, vol.96
, Issue.3
, pp. 308-318
-
-
Skurk, C.1
Maatz, H.2
Rocnik, E.3
Bialik, A.4
Force, T.5
Walsh, K.6
-
86
-
-
79956328903
-
Molecular mechanisms and clinical applications of angiogenesis
-
COI: 1:CAS:528:DC%2BC3MXmtlemurg%3D
-
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298–307
-
(2011)
Nature
, vol.473
, Issue.7347
, pp. 298-307
-
-
Carmeliet, P.1
Jain, R.K.2
-
87
-
-
84861660394
-
Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo
-
COI: 1:CAS:528:DC%2BC3MXhtlartrvN
-
Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S, Queimado L (2012) Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene 31(22):2725–2737
-
(2012)
Oncogene
, vol.31
, Issue.22
, pp. 2725-2737
-
-
Ramachandran, I.1
Thavathiru, E.2
Ramalingam, S.3
Natarajan, G.4
Mills, W.K.5
Benbrook, D.M.6
Zuna, R.7
Lightfoot, S.8
Reis, A.9
Anant, S.10
Queimado, L.11
-
88
-
-
58549108465
-
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells
-
COI: 1:CAS:528:DC%2BD1MXhtFemt7w%3D
-
Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G (2009) Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 379(3):726–731
-
(2009)
Biochem Biophys Res Commun
, vol.379
, Issue.3
, pp. 726-731
-
-
Saito, Y.1
Friedman, J.M.2
Chihara, Y.3
Egger, G.4
Chuang, J.C.5
Liang, G.6
-
90
-
-
84875808286
-
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis
-
COI: 1:CAS:528:DC%2BC38XhvVektrzK
-
Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R, Borden EC (2013) Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol 32(2):123–132
-
(2013)
Matrix Biol
, vol.32
, Issue.2
, pp. 123-132
-
-
Lindner, D.J.1
Wu, Y.2
Haney, R.3
Jacobs, B.S.4
Fruehauf, J.P.5
Tuthill, R.6
Borden, E.C.7
-
91
-
-
65849274263
-
Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments
-
COI: 1:CAS:528:DC%2BD1cXht1ygt7fI
-
Mirochnik Y, Kwiatek A, Volpert O (2008) Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 9(10):851–862
-
(2008)
Curr Drug Targets
, vol.9
, Issue.10
, pp. 851-862
-
-
Mirochnik, Y.1
Kwiatek, A.2
Volpert, O.3
-
92
-
-
84988360828
-
Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
-
Jueliger S, Lyons J, Cannito S, Pata I, Pata P, Shkolnaya M, Lo Re O, Peyrou M, Villarroya F, Pazienza V, Rappa F, Cappello F, Azab M, Taverna P, Vinciguerra M (2016) Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. Epigenetics 11(10):709–720
-
(2016)
Epigenetics
, vol.11
, Issue.10
, pp. 709-720
-
-
Jueliger, S.1
Lyons, J.2
Cannito, S.3
Pata, I.4
Pata, P.5
Shkolnaya, M.6
Lo Re, O.7
Peyrou, M.8
Villarroya, F.9
Pazienza, V.10
Rappa, F.11
Cappello, F.12
Azab, M.13
Taverna, P.14
Vinciguerra, M.15
-
93
-
-
78449267307
-
DLC1 negatively regulates angiogenesis in a paracrine fashion
-
COI: 1:CAS:528:DC%2BC3cXhtlKjtrjE
-
Shih YP, Liao YC, Lin Y, Lo SH (2010) DLC1 negatively regulates angiogenesis in a paracrine fashion. Cancer Res 70(21):8270–8275
-
(2010)
Cancer Res
, vol.70
, Issue.21
, pp. 8270-8275
-
-
Shih, Y.P.1
Liao, Y.C.2
Lin, Y.3
Lo, S.H.4
-
94
-
-
48149105835
-
Anti-angiogenesis: making the tumor vulnerable to the immune system
-
COI: 1:CAS:528:DC%2BD1cXovFyitr8%3D
-
Griffioen AW (2008) Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol Immunother 57(10):1553–1558
-
(2008)
Cancer Immunol Immunother
, vol.57
, Issue.10
, pp. 1553-1558
-
-
Griffioen, A.W.1
-
95
-
-
33644990380
-
Angiostatic activity of DNA methyltransferase inhibitors
-
COI: 1:CAS:528:DC%2BD28XhvVelsbg%3D
-
Hellebrekers DMEI, Jair K-W, Viré E, Eguchi S, Hoebers NTH, Fraga MF, Esteller M, Fuks F, Baylin SB, van Engeland M, Griffioen AW (2006) Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 5(2):467–475
-
(2006)
Mol Cancer Ther
, vol.5
, Issue.2
, pp. 467-475
-
-
Hellebrekers, D.M.E.I.1
Jair, K.-W.2
Viré, E.3
Eguchi, S.4
Hoebers, N.T.H.5
Fraga, M.F.6
Esteller, M.7
Fuks, F.8
Baylin, S.B.9
van Engeland, M.10
Griffioen, A.W.11
-
96
-
-
84908696558
-
The RECK gene and biological malignancy-its significance in angiogenesis and inhibition of matrix metalloproteinases
-
COI: 1:CAS:528:DC%2BC2cXhsFKrsr3N
-
Alexius-Lindgren M, Andersson E, Lindstedt I, Engström W (2014) The RECK gene and biological malignancy-its significance in angiogenesis and inhibition of matrix metalloproteinases. Anticancer Res 34(8):3867–3874
-
(2014)
Anticancer Res
, vol.34
, Issue.8
, pp. 3867-3874
-
-
Alexius-Lindgren, M.1
Andersson, E.2
Lindstedt, I.3
Engström, W.4
-
97
-
-
0142148099
-
Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram
-
Shian S-G, Kao Y-R, Wu FY-H, Wu C-W (2003) Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol 64(5):1076–1084
-
(2003)
Mol Pharmacol
, vol.64
, Issue.5
, pp. 1076-1084
-
-
Shian, S.-G.1
Kao, Y.-R.2
Wu, F.Y.-H.3
Wu, C.-W.4
-
98
-
-
80052055075
-
A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs
-
Murai R, Yoshida Y, Muraguchi T, Nishimoto E, Morioka Y, Kitayama H, Kondoh S, Kawazoe Y, Hiraoka M, Uesugi M, Noda M (2010) A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget 1(4):252–264
-
(2010)
Oncotarget
, vol.1
, Issue.4
, pp. 252-264
-
-
Murai, R.1
Yoshida, Y.2
Muraguchi, T.3
Nishimoto, E.4
Morioka, Y.5
Kitayama, H.6
Kondoh, S.7
Kawazoe, Y.8
Hiraoka, M.9
Uesugi, M.10
Noda, M.11
-
99
-
-
84906279008
-
Anti-neoplastic properties of hydralazine in prostate cancer
-
Graça I, Sousa EJ, Costa-Pinheiro P, Vieira FQ, Torres-Ferreira J, Martins MG, Henrique R, Jerónimo C (2014) Anti-neoplastic properties of hydralazine in prostate cancer. Oncotarget 5(15):5950–5964
-
(2014)
Oncotarget
, vol.5
, Issue.15
, pp. 5950-5964
-
-
Graça, I.1
Sousa, E.J.2
Costa-Pinheiro, P.3
Vieira, F.Q.4
Torres-Ferreira, J.5
Martins, M.G.6
Henrique, R.7
Jerónimo, C.8
-
100
-
-
33645071947
-
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
-
Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G, Duenas-Gonzalez A (2006) Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int. doi:10.1186/1475-2867-6-2
-
(2006)
Cancer Cell Int
-
-
Chavez-Blanco, A.1
Perez-Plasencia, C.2
Perez-Cardenas, E.3
Carrasco-Legleu, C.4
Rangel-Lopez, E.5
Segura-Pacheco, B.6
Taja-Chayeb, L.7
Trejo-Becerril, C.8
Gonzalez-Fierro, A.9
Candelaria, M.10
Cabrera, G.11
Duenas-Gonzalez, A.12
-
101
-
-
84961167044
-
In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent
-
COI: 1:CAS:528:DC%2BC28XksVWht70%3D
-
Zhang Q, Lin Z, Yin X, Tang L, Luo H, Li H, Zhang Y, Luo W (2016) In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent. Eur J Pharmacol 779:138–146
-
(2016)
Eur J Pharmacol
, vol.779
, pp. 138-146
-
-
Zhang, Q.1
Lin, Z.2
Yin, X.3
Tang, L.4
Luo, H.5
Li, H.6
Zhang, Y.7
Luo, W.8
-
102
-
-
84885646525
-
Epigallocatechin-3-gallate inhibits IGF-I-stimulated lung cancer angiogenesis through downregulation of HIF-1α and VEGF expression
-
Li X, Feng Y, Liu J, Feng X, Zhou K, Tang X (2013) Epigallocatechin-3-gallate inhibits IGF-I-stimulated lung cancer angiogenesis through downregulation of HIF-1α and VEGF expression. J Nutrigenet Nutrigenom 6(3):169–178
-
(2013)
J Nutrigenet Nutrigenom
, vol.6
, Issue.3
, pp. 169-178
-
-
Li, X.1
Feng, Y.2
Liu, J.3
Feng, X.4
Zhou, K.5
Tang, X.6
-
103
-
-
84884632449
-
Effects of epigallocatechin-3-gallate (EGCG) on A549 lung cancer tumor growth and angiogenesis
-
COI: 1:CAS:528:DC%2BC3sXhsF2ksbrF
-
Sakamoto Y, Terashita N, Muraguchi T, Fukusato T, Kubota S (2013) Effects of epigallocatechin-3-gallate (EGCG) on A549 lung cancer tumor growth and angiogenesis. Biosci Biotechnol Biochem 77(9):1799–1803
-
(2013)
Biosci Biotechnol Biochem
, vol.77
, Issue.9
, pp. 1799-1803
-
-
Sakamoto, Y.1
Terashita, N.2
Muraguchi, T.3
Fukusato, T.4
Kubota, S.5
-
104
-
-
84877314894
-
EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1alpha and NFkappaB, and VEGF expression
-
COI: 1:CAS:528:DC%2BC3sXot1ygtbY%3D
-
Gu J, Makey KL, Tucker KB, Chinchar E, Mao X, Pei I, Thomas EY, Miele L (2013) EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1alpha and NFkappaB, and VEGF expression. Vasc Cell 5(1):9
-
(2013)
Vasc Cell
, vol.5
, Issue.1
, pp. 9
-
-
Gu, J.1
Makey, K.L.2
Tucker, K.B.3
Chinchar, E.4
Mao, X.5
Pei, I.6
Thomas, E.Y.7
Miele, L.8
-
105
-
-
49549087270
-
Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells
-
COI: 1:CAS:528:DC%2BD1cXpslWrt7c%3D
-
Kato K, Long NK, Makita H, Toida M, Yamashita T, Hatakeyama D, Hara A, Mori H, Shibata T (2008) Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br J Cancer 99(4):647–654
-
(2008)
Br J Cancer
, vol.99
, Issue.4
, pp. 647-654
-
-
Kato, K.1
Long, N.K.2
Makita, H.3
Toida, M.4
Yamashita, T.5
Hatakeyama, D.6
Hara, A.7
Mori, H.8
Shibata, T.9
-
106
-
-
51349137454
-
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins
-
COI: 1:CAS:528:DC%2BD1cXhtFWlsrjM
-
Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269(2):199–225
-
(2008)
Cancer Lett
, vol.269
, Issue.2
, pp. 199-225
-
-
Kunnumakkara, A.B.1
Anand, P.2
Aggarwal, B.B.3
-
107
-
-
0031840433
-
Curcumin is an in vivo inhibitor of angiogenesis
-
COI: 1:CAS:528:DyaK1cXksFKktbc%3D
-
Arbiser JL, Klauber N, Rohan R, van Leeuwen R, Huang MT, Fisher C, Flynn E, Byers HR (1998) Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4(6):376–383
-
(1998)
Mol Med
, vol.4
, Issue.6
, pp. 376-383
-
-
Arbiser, J.L.1
Klauber, N.2
Rohan, R.3
van Leeuwen, R.4
Huang, M.T.5
Fisher, C.6
Flynn, E.7
Byers, H.R.8
-
108
-
-
84873710074
-
Reactivation of RASSF1A in breast cancer cells by curcumin
-
COI: 1:CAS:528:DC%2BC38Xhs1OmsrbO
-
Du L, Xie Z, Wu LC, Chiu M, Lin J, Chan KK, Liu S, Liu Z (2012) Reactivation of RASSF1A in breast cancer cells by curcumin. Nutr Cancer Int J 64(8):1228–1235
-
(2012)
Nutr Cancer Int J
, vol.64
, Issue.8
, pp. 1228-1235
-
-
Du, L.1
Xie, Z.2
Wu, L.C.3
Chiu, M.4
Lin, J.5
Chan, K.K.6
Liu, S.7
Liu, Z.8
-
109
-
-
84876084653
-
Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins
-
Mirza S, Sharma G, Parshad R, Gupta SD, Pandya P, Ralhan R (2013) Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J Breast Cancer 16(1):23–31
-
(2013)
J Breast Cancer
, vol.16
, Issue.1
, pp. 23-31
-
-
Mirza, S.1
Sharma, G.2
Parshad, R.3
Gupta, S.D.4
Pandya, P.5
Ralhan, R.6
-
110
-
-
84883387232
-
Curcumin as a regulator of epigenetic events
-
COI: 1:CAS:528:DC%2BC3sXptV2gtrk%3D
-
Teiten MH, Dicato M, Diederich M (2013) Curcumin as a regulator of epigenetic events. Mol Nutr Food Res 57(9):1619–1629
-
(2013)
Mol Nutr Food Res
, vol.57
, Issue.9
, pp. 1619-1629
-
-
Teiten, M.H.1
Dicato, M.2
Diederich, M.3
-
111
-
-
84864357972
-
Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer
-
COI: 1:CAS:528:DC%2BC38XhtVOisr3I
-
Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB (2012) Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev 21(5):407–412
-
(2012)
Eur J Cancer Prev
, vol.21
, Issue.5
, pp. 407-412
-
-
Alexandrow, M.G.1
Song, L.J.2
Altiok, S.3
Gray, J.4
Haura, E.B.5
Kumar, N.B.6
-
112
-
-
85047695527
-
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
-
COI: 1:CAS:528:DC%2BD38XivVelur4%3D
-
Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000–2008
-
(2002)
Oncogene
, vol.21
, Issue.13
, pp. 2000-2008
-
-
Niu, G.1
Wright, K.L.2
Huang, M.3
Song, L.4
Haura, E.5
Turkson, J.6
Zhang, S.7
Wang, T.8
Sinibaldi, D.9
Coppola, D.10
Heller, R.11
Ellis, L.M.12
Karras, J.13
Bromberg, J.14
Pardoll, D.15
Jove, R.16
Yu, H.17
-
113
-
-
0037461934
-
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis
-
COI: 1:CAS:528:DC%2BD3sXlsV2ltA%3D%3D
-
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22(3):319–329
-
(2003)
Oncogene
, vol.22
, Issue.3
, pp. 319-329
-
-
Wei, D.1
Le, X.2
Zheng, L.3
Wang, L.4
Frey, J.A.5
Gao, A.C.6
Peng, Z.7
Huang, S.8
Xiong, H.Q.9
Abbruzzese, J.L.10
Xie, K.11
-
114
-
-
84861215508
-
Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation
-
COI: 1:CAS:528:DC%2BC38Xot1Kntrw%3D
-
Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, Hoon DSB, Forman SJ, Jove R, Riggs AD, Yu H (2012) Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci 109(20):7765–7769
-
(2012)
Proc Natl Acad Sci
, vol.109
, Issue.20
, pp. 7765-7769
-
-
Lee, H.1
Zhang, P.2
Herrmann, A.3
Yang, C.4
Xin, H.5
Wang, Z.6
Hoon, D.S.B.7
Forman, S.J.8
Jove, R.9
Riggs, A.D.10
Yu, H.11
-
115
-
-
84959550810
-
Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis
-
Huang L, Hu B, Ni J, Wu J, Jiang W, Chen C, Yang L, Zeng Y, Wan R, Hu G, Wang X (2016) Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. J Exp Clin Cancer Res 35(1):27
-
(2016)
J Exp Clin Cancer Res
, vol.35
, Issue.1
, pp. 27
-
-
Huang, L.1
Hu, B.2
Ni, J.3
Wu, J.4
Jiang, W.5
Chen, C.6
Yang, L.7
Zeng, Y.8
Wan, R.9
Hu, G.10
Wang, X.11
-
116
-
-
84867314763
-
SOCS3 is an endogenous inhibitor of pathologic angiogenesis
-
COI: 1:CAS:528:DC%2BC38XhsFaksLfO
-
Stahl A, Joyal JS, Chen J, Sapieha P, Juan AM, Hatton CJ, Pei DT, Hurst CG, Seaward MR, Krah NM, Dennison RJ, Greene ER, Boscolo E, Panigrahy D, Smith LEH (2012) SOCS3 is an endogenous inhibitor of pathologic angiogenesis. Blood 120(14):2925–2929
-
(2012)
Blood
, vol.120
, Issue.14
, pp. 2925-2929
-
-
Stahl, A.1
Joyal, J.S.2
Chen, J.3
Sapieha, P.4
Juan, A.M.5
Hatton, C.J.6
Pei, D.T.7
Hurst, C.G.8
Seaward, M.R.9
Krah, N.M.10
Dennison, R.J.11
Greene, E.R.12
Boscolo, E.13
Panigrahy, D.14
Smith, L.E.H.15
-
117
-
-
51649118928
-
Phase II trial of curcumin in patients with advanced pancreatic cancer
-
COI: 1:CAS:528:DC%2BD1cXosFGitLw%3D
-
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14(14):4491–4499
-
(2008)
Clin Cancer Res
, vol.14
, Issue.14
, pp. 4491-4499
-
-
Dhillon, N.1
Aggarwal, B.B.2
Newman, R.A.3
Wolff, R.A.4
Kunnumakkara, A.B.5
Abbruzzese, J.L.6
Ng, C.S.7
Badmaev, V.8
Kurzrock, R.9
-
118
-
-
85009775757
-
A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin
-
Licona C, Spaety M-E, Capuozzo A, Ali M, Santamaria R, Armant O, Delalande F, Van Dorsselaer A, Cianferani S, Spencer J, Pfeffer M, Mellitzer G, Gaiddon C (2017) A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. Oncotarget 8(2):2568–2584
-
(2017)
Oncotarget
, vol.8
, Issue.2
, pp. 2568-2584
-
-
Licona, C.1
Spaety, M.-E.2
Capuozzo, A.3
Ali, M.4
Santamaria, R.5
Armant, O.6
Delalande, F.7
Van Dorsselaer, A.8
Cianferani, S.9
Spencer, J.10
Pfeffer, M.11
Mellitzer, G.12
Gaiddon, C.13
-
119
-
-
84875786277
-
Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters
-
Nazarov AA, Baquié M, Nowak-Sliwinska P, Zava O, van Beijnum JR, Groessl M, Chisholm DM, Ahmadi Z, McIndoe JS, Griffioen AW, van den Bergh H, Dyson PJ (2013) Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters. Sci Rep 3:1485
-
(2013)
Sci Rep
, vol.3
, pp. 1485
-
-
Nazarov, A.A.1
Baquié, M.2
Nowak-Sliwinska, P.3
Zava, O.4
van Beijnum, J.R.5
Groessl, M.6
Chisholm, D.M.7
Ahmadi, Z.8
McIndoe, J.S.9
Griffioen, A.W.10
van den Bergh, H.11
Dyson, P.J.12
-
120
-
-
84899518652
-
Discovery of a highly tumor-selective organometallic ruthenium(II)-arene complex
-
COI: 1:CAS:528:DC%2BC2cXkvFylur0%3D
-
Clavel CM, Păunescu E, Nowak-Sliwinska P, Griffioen AW, Scopelliti R, Dyson PJ (2014) Discovery of a highly tumor-selective organometallic ruthenium(II)-arene complex. J Med Chem 57(8):3546–3558
-
(2014)
J Med Chem
, vol.57
, Issue.8
, pp. 3546-3558
-
-
Clavel, C.M.1
Păunescu, E.2
Nowak-Sliwinska, P.3
Griffioen, A.W.4
Scopelliti, R.5
Dyson, P.J.6
-
121
-
-
84959211586
-
Metal-based drugs that break the rules
-
COI: 1:CAS:528:DC%2BC28XhsFymurs%3D
-
Allardyce CS, Dyson PJ (2016) Metal-based drugs that break the rules. Dalton Trans 45(8):3201–3209
-
(2016)
Dalton Trans
, vol.45
, Issue.8
, pp. 3201-3209
-
-
Allardyce, C.S.1
Dyson, P.J.2
-
122
-
-
84896071887
-
Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae
-
COI: 1:CAS:528:DC%2BC2cXjtlSrsrc%3D
-
Singh V, Azad GK, Mandal P, Amarendar Reddy M, Tomar RS (2014) Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae. FEBS Lett 588(6):1044–1052
-
(2014)
FEBS Lett
, vol.588
, Issue.6
, pp. 1044-1052
-
-
Singh, V.1
Azad, G.K.2
Mandal, P.3
Amarendar Reddy, M.4
Tomar, R.S.5
-
123
-
-
84922005327
-
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
-
COI: 1:CAS:528:DC%2BC2cXhvFShsLvI
-
Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, Van Werkhoven E, Alessio E, Sava G, Beijnen JH, Schellens JHM (2015) Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investig New Drugs 33(1):201–214
-
(2015)
Investig New Drugs
, vol.33
, Issue.1
, pp. 201-214
-
-
Leijen, S.1
Burgers, S.A.2
Baas, P.3
Pluim, D.4
Tibben, M.5
Van Werkhoven, E.6
Alessio, E.7
Sava, G.8
Beijnen, J.H.9
Schellens, J.H.M.10
-
124
-
-
2542625358
-
A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent
-
COI: 1:CAS:528:DC%2BD2cXksVKntr8%3D
-
Rademaker-Lakhai JM, Van Den Bongard D, Pluim D, Beijnen JH, Schellens JHM (2004) A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 10:3717–3727
-
(2004)
Clin Cancer Res
, vol.10
, pp. 3717-3727
-
-
Rademaker-Lakhai, J.M.1
Van Den Bongard, D.2
Pluim, D.3
Beijnen, J.H.4
Schellens, J.H.M.5
-
125
-
-
58149339989
-
KP1019, a new redox-active anticancer agent—preclinical development and results of a clinical phase I study in tumor patients
-
COI: 1:CAS:528:DC%2BD1cXhsVWktLvO
-
Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson PJ, Keppler BK (2008) KP1019, a new redox-active anticancer agent—preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers 5(10):2140–2155
-
(2008)
Chem Biodivers
, vol.5
, Issue.10
, pp. 2140-2155
-
-
Hartinger, C.G.1
Jakupec, M.A.2
Zorbas-Seifried, S.3
Groessl, M.4
Egger, A.5
Berger, W.6
Zorbas, H.7
Dyson, P.J.8
Keppler, B.K.9
-
126
-
-
84903745805
-
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
-
COI: 1:CAS:528:DC%2BC2cXhtVOiurbM
-
Trondl R, Heffeter P, Kowol CR, Jakupec MA, Berger W, Keppler BK (2014) NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chem Sci 5(8):2925
-
(2014)
Chem Sci
, vol.5
, Issue.8
, pp. 2925
-
-
Trondl, R.1
Heffeter, P.2
Kowol, C.R.3
Jakupec, M.A.4
Berger, W.5
Keppler, B.K.6
-
127
-
-
0037987890
-
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
-
COI: 1:CAS:528:DC%2BD3sXktFOgu7w%3D
-
Morbidelli L, Donnini S, Filippi S, Messori L, Piccioli F, Orioli P, Sava G, Ziche M (2003) Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. Br J Cancer 88(9):1484–1491
-
(2003)
Br J Cancer
, vol.88
, Issue.9
, pp. 1484-1491
-
-
Morbidelli, L.1
Donnini, S.2
Filippi, S.3
Messori, L.4
Piccioli, F.5
Orioli, P.6
Sava, G.7
Ziche, M.8
-
128
-
-
0036445261
-
Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation
-
COI: 1:CAS:528:DC%2BD38XpsVOqt7g%3D
-
Pintus G, Tadolini B, Posadino AM, Sanna B, Debidda M, Bennardini F, Sava G, Ventura C (2002) Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur J Biochem 269(23):5861–5870
-
(2002)
Eur J Biochem
, vol.269
, Issue.23
, pp. 5861-5870
-
-
Pintus, G.1
Tadolini, B.2
Posadino, A.M.3
Sanna, B.4
Debidda, M.5
Bennardini, F.6
Sava, G.7
Ventura, C.8
-
129
-
-
0037128713
-
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
-
COI: 1:CAS:528:DC%2BD38XjsVyqt7k%3D
-
Vacca A, Bruno M, Boccarelli A, Coluccia M, Ribatti D, Bergamo A, Garbisa S, Sartor L, Sava G (2002) Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br J Cancer 86(6):993–998
-
(2002)
Br J Cancer
, vol.86
, Issue.6
, pp. 993-998
-
-
Vacca, A.1
Bruno, M.2
Boccarelli, A.3
Coluccia, M.4
Ribatti, D.5
Bergamo, A.6
Garbisa, S.7
Sartor, L.8
Sava, G.9
-
130
-
-
62449161586
-
Bioorganometallic chemistry–from teaching paradigms to medicinal applications
-
COI: 1:CAS:528:DC%2BD1MXksVSntLs%3D
-
Hartinger CG, Dyson PJ (2009) Bioorganometallic chemistry–from teaching paradigms to medicinal applications. Chem Soc Rev 38(2):391–401
-
(2009)
Chem Soc Rev
, vol.38
, Issue.2
, pp. 391-401
-
-
Hartinger, C.G.1
Dyson, P.J.2
-
131
-
-
80053999836
-
Targeted and multifunctional arene ruthenium chemotherapeutics
-
COI: 1:CAS:528:DC%2BC3MXhtlShu73J
-
Smith GS, Therrien B (2011) Targeted and multifunctional arene ruthenium chemotherapeutics. Dalton Trans 40(41):10793
-
(2011)
Dalton Trans
, vol.40
, Issue.41
, pp. 10793
-
-
Smith, G.S.1
Therrien, B.2
-
132
-
-
84893262070
-
Water-soluble arene ruthenium complexes: from serendipity to catalysis and drug design
-
Süss-Fink G (2014) Water-soluble arene ruthenium complexes: from serendipity to catalysis and drug design. J Organomet Chem 751:2–19
-
(2014)
J Organomet Chem
, vol.751
, pp. 2-19
-
-
Süss-Fink, G.1
-
133
-
-
84982077068
-
The development of RAPTA compounds for the treatment of tumors
-
COI: 1:CAS:528:DC%2BC2MXhtFCqtL7M
-
Murray BS, Babak MV, Hartinger CG, Dyson PJ (2016) The development of RAPTA compounds for the treatment of tumors. Coord Chem Rev 306:86–114
-
(2016)
Coord Chem Rev
, vol.306
, pp. 86-114
-
-
Murray, B.S.1
Babak, M.V.2
Hartinger, C.G.3
Dyson, P.J.4
-
134
-
-
20444400159
-
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes
-
COI: 1:CAS:528:DC%2BD2MXktlCrsL0%3D
-
Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G, Dyson PJ (2005) In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem 48:4161–4171
-
(2005)
J Med Chem
, vol.48
, pp. 4161-4171
-
-
Scolaro, C.1
Bergamo, A.2
Brescacin, L.3
Delfino, R.4
Cocchietto, M.5
Laurenczy, G.6
Geldbach, T.J.7
Sava, G.8
Dyson, P.J.9
-
135
-
-
84908452599
-
2 (pta)] (RAPTA-C) in human ovarian and colorectal carcinomas
-
COI: 1:CAS:528:DC%2BC2cXht1KktLjE
-
2 (pta)] (RAPTA-C) in human ovarian and colorectal carcinomas. Chem Sci 5(12):4742–4748
-
(2014)
Chem Sci
, vol.5
, Issue.12
, pp. 4742-4748
-
-
Weiss, A.1
Berndsen, R.H.2
Dubois, M.3
Müller, C.4
Schibli, R.5
Griffioen, A.W.6
Dyson, P.J.7
Nowak-Sliwinska, P.8
-
136
-
-
79958079501
-
Organometallic ruthenium(II) arene compounds with antiangiogenic activity
-
COI: 1:CAS:528:DC%2BC3MXmtFWqs7s%3D
-
Nowak-Sliwinska P, Van Beijnum JR, Casini A, Nazarov AA, Wagnieres G, Van Den Bergh H, Dyson PJ, Griffioen AW (2011) Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem 54(11):3895–3902
-
(2011)
J Med Chem
, vol.54
, Issue.11
, pp. 3895-3902
-
-
Nowak-Sliwinska, P.1
Van Beijnum, J.R.2
Casini, A.3
Nazarov, A.A.4
Wagnieres, G.5
Van Den Bergh, H.6
Dyson, P.J.7
Griffioen, A.W.8
-
137
-
-
33749011163
-
The NCI60 human tumour cell line anticancer drug screen
-
COI: 1:CAS:528:DC%2BD28XpvVCmu7c%3D
-
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6(10):813–823
-
(2006)
Nat Rev Cancer
, vol.6
, Issue.10
, pp. 813-823
-
-
Shoemaker, R.H.1
-
138
-
-
84897031169
-
Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity
-
Adhireksan Z, Davey GE, Campomanes P, Groessl M, Clavel CM, Yu H, Nazarov AA, Yeo CHF, Ang WH, Dröge P, Rothlisberger U, Dyson PJ, Davey CA (2014) Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity. Nat Commun 5:3462
-
(2014)
Nat Commun
, vol.5
, pp. 3462
-
-
Adhireksan, Z.1
Davey, G.E.2
Campomanes, P.3
Groessl, M.4
Clavel, C.M.5
Yu, H.6
Nazarov, A.A.7
Yeo, C.H.F.8
Ang, W.H.9
Dröge, P.10
Rothlisberger, U.11
Dyson, P.J.12
Davey, C.A.13
-
139
-
-
84907593135
-
The chicken chorioallantoic membrane model in biology, medicine and bioengineering
-
Nowak-Sliwinska P, Segura T, Iruela-Arispe ML (2014) The chicken chorioallantoic membrane model in biology, medicine and bioengineering. Angiogenesis 4:779–804
-
(2014)
Angiogenesis
, vol.4
, pp. 779-804
-
-
Nowak-Sliwinska, P.1
Segura, T.2
Iruela-Arispe, M.L.3
-
140
-
-
84946780107
-
NanoSIMS analysis of an isotopically labelled organometallic ruthenium(II) drug to probe its distribution and state in vitro
-
COI: 1:CAS:528:DC%2BC2MXhsFCitr3E
-
Lee RFS, Escrig S, Croisier M, Clerc-Rosset S, Knott GW, Meibom A, Davey CA, Johnsson K, Dyson PJ (2015) NanoSIMS analysis of an isotopically labelled organometallic ruthenium(II) drug to probe its distribution and state in vitro. Chem Commun (Camb) 51(92):16486–16489
-
(2015)
Chem Commun (Camb)
, vol.51
, Issue.92
, pp. 16486-16489
-
-
Lee, R.F.S.1
Escrig, S.2
Croisier, M.3
Clerc-Rosset, S.4
Knott, G.W.5
Meibom, A.6
Davey, C.A.7
Johnsson, K.8
Dyson, P.J.9
-
141
-
-
79952593681
-
A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core
-
COI: 1:CAS:528:DC%2BC3MXjtFWnsLk%3D
-
Wu B, Ong MS, Groessl M, Adhireksan Z, Hartinger CG, Dyson PJ, Davey CA (2011) A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. Chemistry 17(13):3562–3566
-
(2011)
Chemistry
, vol.17
, Issue.13
, pp. 3562-3566
-
-
Wu, B.1
Ong, M.S.2
Groessl, M.3
Adhireksan, Z.4
Hartinger, C.G.5
Dyson, P.J.6
Davey, C.A.7
-
142
-
-
85016557265
-
-
Allosteric cross-talk in chromatin can mediate drug-drug synergy, Nat Commun
-
Adhireksan Z, Palermo G, Riedel T, Ma Z, Muhammad R, Röthlisberger U, Dyson PJ, Davey CA (2017) Allosteric cross-talk in chromatin can mediate drug-drug synergy. Nat Commun. doi:10.1038/ncomms14860
-
(2017)
Davey CA
-
-
Adhireksan, Z.1
Palermo, G.2
Riedel, T.3
Ma, Z.4
Muhammad, R.5
Röthlisberger, U.6
Dyson, P.J.7
-
143
-
-
85019530384
-
Current trends in multidrug optimization
-
Weiss A, Nowak-Sliwinska P (2016) Current trends in multidrug optimization. J Lab Autom. doi:10.1177/2211068216682338
-
(2016)
J Lab Autom
-
-
Weiss, A.1
Nowak-Sliwinska, P.2
-
144
-
-
84961318149
-
Optimization of drug combinations using feedback system control
-
COI: 1:CAS:528:DC%2BC28XlvVGrtw%3D%3D
-
Nowak-Sliwinska P, Weiss A, Ding X, Dyson PJ, van den Bergh H, Griffioen AW, Ho C-M (2016) Optimization of drug combinations using feedback system control. Nat Protoc 11(2):302–315. doi:10.1177/2472630316682338
-
(2016)
Nat Protoc
, vol.11
, Issue.2
, pp. 302-315
-
-
Nowak-Sliwinska, P.1
Weiss, A.2
Ding, X.3
Dyson, P.J.4
van den Bergh, H.5
Griffioen, A.W.6
Ho, C.-M.7
-
145
-
-
84931563239
-
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
-
COI: 1:CAS:528:DC%2BC2MXlvFelu7k%3D
-
Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga M, Shen L, Schlingemann RO, Pili R, Ho C-M, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P (2015) Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis 18(3):233–244
-
(2015)
Angiogenesis
, vol.18
, Issue.3
, pp. 233-244
-
-
Weiss, A.1
Ding, X.2
van Beijnum, J.R.3
Wong, I.4
Wong, T.J.5
Berndsen, R.H.6
Dormond, O.7
Dallinga, M.8
Shen, L.9
Schlingemann, R.O.10
Pili, R.11
Ho, C.-M.12
Dyson, P.J.13
van den Bergh, H.14
Griffioen, A.W.15
Nowak-Sliwinska, P.16
-
146
-
-
84934269303
-
Episensitization: defying time’s arrow
-
Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR (2015) Episensitization: defying time’s arrow. Front Oncol. doi:10.3389/fonc.2015.00134
-
(2015)
Front Oncol
-
-
Oronsky, B.T.1
Oronsky, A.L.2
Lybeck, M.3
Oronsky, N.C.4
Scicinski, J.J.5
Carter, C.6
Day, R.M.7
Rodriguez Orengo, J.F.8
Rodriguez-Torres, M.9
Fanger, G.F.10
Reid, T.R.11
-
147
-
-
79956126234
-
Synthesis and biological evaluation of JAHAs: ferrocene-based histone deacetylase inhibitors
-
COI: 1:CAS:528:DC%2BC3MXjsVCmsL8%3D
-
Spencer J, Amin J, Wang M, Packham G, Alwi SSS, Tizzard GJ, Coles SJ, Paranal RM, Bradner JE, Heightman TD (2011) Synthesis and biological evaluation of JAHAs: ferrocene-based histone deacetylase inhibitors. ACS Med Chem Lett 2(5):358–362
-
(2011)
ACS Med Chem Lett
, vol.2
, Issue.5
, pp. 358-362
-
-
Spencer, J.1
Amin, J.2
Wang, M.3
Packham, G.4
Alwi, S.S.S.5
Tizzard, G.J.6
Coles, S.J.7
Paranal, R.M.8
Bradner, J.E.9
Heightman, T.D.10
-
148
-
-
84869453615
-
Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class i histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells
-
COI: 1:CAS:528:DC%2BC38XhsFGmtLnM
-
Librizzi M, Longo A, Chiarelli R, Amin J, Spencer J, Luparello C (2012) Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class i histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells. Chem Res Toxicol 25(11):2608–2616
-
(2012)
Chem Res Toxicol
, vol.25
, Issue.11
, pp. 2608-2616
-
-
Librizzi, M.1
Longo, A.2
Chiarelli, R.3
Amin, J.4
Spencer, J.5
Luparello, C.6
-
149
-
-
78751590899
-
Silencing chromatin: comparing modes and mechanisms
-
COI: 1:CAS:528:DC%2BC3MXmsVelsQ%3D%3D
-
Beisel C, Paro R (2011) Silencing chromatin: comparing modes and mechanisms. Nat Rev Genet 12(2):123–135
-
(2011)
Nat Rev Genet
, vol.12
, Issue.2
, pp. 123-135
-
-
Beisel, C.1
Paro, R.2
-
150
-
-
0033919595
-
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters
-
COI: 1:CAS:528:DC%2BD3cXkvFKkt7Y%3D
-
Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25(3):338–342
-
(2000)
Nat Genet
, vol.25
, Issue.3
, pp. 338-342
-
-
Robertson, K.D.1
Ait-Si-Ali, S.2
Yokochi, T.3
Wade, P.A.4
Jones, P.L.5
Wolffe, A.P.6
-
151
-
-
0033945861
-
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci
-
COI: 1:CAS:528:DC%2BD3cXkvFKltLk%3D
-
Rountree MR, Bachman KE, Baylin SB (2000) DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25(3):269–277
-
(2000)
Nat Genet
, vol.25
, Issue.3
, pp. 269-277
-
-
Rountree, M.R.1
Bachman, K.E.2
Baylin, S.B.3
-
152
-
-
84893742589
-
Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network
-
COI: 1:CAS:528:DC%2BC2cXhsFensrk%3D
-
Shiva Shankar TV, Willems L (2014) Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network. Vasc Pharmacol 60(2):57–66
-
(2014)
Vasc Pharmacol
, vol.60
, Issue.2
, pp. 57-66
-
-
Shiva Shankar, T.V.1
Willems, L.2
-
153
-
-
0000346996
-
Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation
-
COI: 1:CAS:528:DC%2BD3cXjvVGhtw%3D%3D
-
Chen WY, Townes TM (2000) Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc Natl Acad Sci USA 97(1):377–382
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, Issue.1
, pp. 377-382
-
-
Chen, W.Y.1
Townes, T.M.2
-
154
-
-
84863872956
-
Epigenetic interplay of histone modifications and DNA methylation mediated by HDA6
-
COI: 1:CAS:528:DC%2BC38XhslSktr%2FN
-
Liu X, Luo M, Wu K (2012) Epigenetic interplay of histone modifications and DNA methylation mediated by HDA6. Plant Signal Behav 7(6):633–635
-
(2012)
Plant Signal Behav
, vol.7
, Issue.6
, pp. 633-635
-
-
Liu, X.1
Luo, M.2
Wu, K.3
-
155
-
-
0037924433
-
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene
-
COI: 1:CAS:528:DC%2BD3sXhtFamtL8%3D
-
Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, Vogelstein B (2003) Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3(1):89–95
-
(2003)
Cancer Cell
, vol.3
, Issue.1
, pp. 89-95
-
-
Bachman, K.E.1
Park, B.H.2
Rhee, I.3
Rajagopalan, H.4
Herman, J.G.5
Baylin, S.B.6
Kinzler, K.W.7
Vogelstein, B.8
-
156
-
-
0032482974
-
Trichostatin A causes selective loss of DNA methylation in Neurospora
-
COI: 1:CAS:528:DyaK1cXltlClsrk%3D
-
Selker EU (1998) Trichostatin A causes selective loss of DNA methylation in Neurospora. Proc Natl Acad Sci USA 95(16):9430–9435
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, Issue.16
, pp. 9430-9435
-
-
Selker, E.U.1
-
157
-
-
51049117752
-
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells
-
COI: 1:CAS:528:DC%2BD1cXmt1Ojsbo%3D
-
Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE (2008) Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 6(5):873–883
-
(2008)
Mol Cancer Res
, vol.6
, Issue.5
, pp. 873-883
-
-
Zhou, Q.1
Agoston, A.T.2
Atadja, P.3
Nelson, W.G.4
Davidson, N.E.5
-
158
-
-
47849083984
-
Epigenetic interplay between histone modifications and DNA methylation in gene silencing
-
Vaissière T, Sawan C, Herceg Z (2008) Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 659(1–2):40–48
-
(2008)
Mutat Res
, vol.659
, Issue.1-2
, pp. 40-48
-
-
Vaissière, T.1
Sawan, C.2
Herceg, Z.3
-
159
-
-
67349190247
-
Linking DNA methylation and histone modification: patterns and paradigms
-
COI: 1:CAS:528:DC%2BD1MXksF2rsL0%3D
-
Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10(5):295–304
-
(2009)
Nat Rev Genet
, vol.10
, Issue.5
, pp. 295-304
-
-
Cedar, H.1
Bergman, Y.2
-
160
-
-
84888811617
-
Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma
-
COI: 1:CAS:528:DC%2BC2cXntlWnsL4%3D
-
Lyu T, Jia N, Wang J, Yan X, Yu Y, Lu Z, Bast RC, Hua K, Feng W (2013) Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics 8(12):1330–1346
-
(2013)
Epigenetics
, vol.8
, Issue.12
, pp. 1330-1346
-
-
Lyu, T.1
Jia, N.2
Wang, J.3
Yan, X.4
Yu, Y.5
Lu, Z.6
Bast, R.C.7
Hua, K.8
Feng, W.9
-
161
-
-
84867395940
-
DNA methylation inhibitors in cancer: recent and future approaches
-
COI: 1:CAS:528:DC%2BC38Xht12lsLrL
-
Gros C, Fahy J, Halby L, Dufau I, Erdmann A, Gregoire JM, Ausseil F, Vispé S, Arimondo PB (2012) DNA methylation inhibitors in cancer: recent and future approaches. Biochimie 94(11):2280–2296
-
(2012)
Biochimie
, vol.94
, Issue.11
, pp. 2280-2296
-
-
Gros, C.1
Fahy, J.2
Halby, L.3
Dufau, I.4
Erdmann, A.5
Gregoire, J.M.6
Ausseil, F.7
Vispé, S.8
Arimondo, P.B.9
-
162
-
-
0032948005
-
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
-
COI: 1:CAS:528:DyaK1MXltlWjtA%3D%3D
-
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21(1):103–107
-
(1999)
Nat Genet
, vol.21
, Issue.1
, pp. 103-107
-
-
Cameron, E.E.1
Bachman, K.E.2
Myohanen, S.3
Herman, J.G.4
Baylin, S.B.5
-
163
-
-
77953196949
-
p16 Modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells
-
COI: 1:CAS:528:DC%2BC3cXpslOltLk%3D
-
Zhang J, Lu A, Li L, Yue J, Lu Y (2010) p16 Modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells. Cancer Invest 28(6):588–597
-
(2010)
Cancer Invest
, vol.28
, Issue.6
, pp. 588-597
-
-
Zhang, J.1
Lu, A.2
Li, L.3
Yue, J.4
Lu, Y.5
-
164
-
-
0034571056
-
Demethylation by 5-aza-2′-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines
-
COI: 1:STN:280:DC%2BD3Mrkt1Gitw%3D%3D
-
Miki K, Shimizu E, Yano S, Tani K, Sone S (2001) Demethylation by 5-aza-2′-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol Res 12(8):335–342
-
(2001)
Oncol Res
, vol.12
, Issue.8
, pp. 335-342
-
-
Miki, K.1
Shimizu, E.2
Yano, S.3
Tani, K.4
Sone, S.5
-
165
-
-
0030323007
-
A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth
-
COI: 1:CAS:528:DyaK2sXjsVGrsro%3D
-
Anand-Apte B, Bao L, Smith R, Iwata K, Olsen BR, Zetter B, Apte SS (1996) A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 74(6):853–862
-
(1996)
Biochem Cell Biol
, vol.74
, Issue.6
, pp. 853-862
-
-
Anand-Apte, B.1
Bao, L.2
Smith, R.3
Iwata, K.4
Olsen, B.R.5
Zetter, B.6
Apte, S.S.7
-
166
-
-
0037393850
-
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2
-
COI: 1:CAS:528:DC%2BD3sXisVOmu7k%3D
-
Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9(4):407–415
-
(2003)
Nat Med
, vol.9
, Issue.4
, pp. 407-415
-
-
Qi, J.H.1
Ebrahem, Q.2
Moore, N.3
Murphy, G.4
Claesson-Welsh, L.5
Bond, M.6
Baker, A.7
Anand-Apte, B.8
-
167
-
-
69249127912
-
Zebularine-induced reduction in VEGF secretion by HIF-1α degradation in oral squamous cell carcinoma
-
COI: 1:CAS:528:DC%2BD1cXotlyrs74%3D
-
Suzuki M, Shinohara F, Rikiishi H (2008) Zebularine-induced reduction in VEGF secretion by HIF-1α degradation in oral squamous cell carcinoma. Mol Med Rep 1(4):465–471
-
(2008)
Mol Med Rep
, vol.1
, Issue.4
, pp. 465-471
-
-
Suzuki, M.1
Shinohara, F.2
Rikiishi, H.3
-
168
-
-
65349111237
-
Synergistic effect of trichostatin A and 5-aza-2′-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study
-
COI: 1:CAS:528:DC%2BD1MXltVertrc%3D
-
Cecconi D, Donadelli M, Pozza ED, Rinalducci S, Zolla L, Scupoli MT, Righetti PG, Scarpa A, Palmieri M (2009) Synergistic effect of trichostatin A and 5-aza-2′-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics 9(7):1952–1966
-
(2009)
Proteomics
, vol.9
, Issue.7
, pp. 1952-1966
-
-
Cecconi, D.1
Donadelli, M.2
Pozza, E.D.3
Rinalducci, S.4
Zolla, L.5
Scupoli, M.T.6
Righetti, P.G.7
Scarpa, A.8
Palmieri, M.9
-
169
-
-
0037400558
-
Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells
-
COI: 1:CAS:528:DC%2BD3sXhs1Khtrg%3D
-
Shaker S, Bernstein M, Momparler LF, Momparler RL (2003) Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 27(5):437–444
-
(2003)
Leuk Res
, vol.27
, Issue.5
, pp. 437-444
-
-
Shaker, S.1
Bernstein, M.2
Momparler, L.F.3
Momparler, R.L.4
-
170
-
-
37549022694
-
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
-
COI: 1:CAS:528:DC%2BD1cXhvFGhsrk%3D
-
Griffiths EA, Gore SD (2008) DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 45(1):23–30
-
(2008)
Semin Hematol
, vol.45
, Issue.1
, pp. 23-30
-
-
Griffiths, E.A.1
Gore, S.D.2
-
171
-
-
84907689730
-
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
-
COI: 1:CAS:528:DC%2BC2cXhs1ymt7rN
-
Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55(10):2301–2304
-
(2014)
Leuk Lymphoma
, vol.55
, Issue.10
, pp. 2301-2304
-
-
Kirschbaum, M.H.1
Foon, K.A.2
Frankel, P.3
Ruel, C.4
Pulone, B.5
Tuscano, J.M.6
Newman, E.M.7
-
172
-
-
33745714230
-
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
-
COI: 1:CAS:528:DC%2BD28XlvVSkurc%3D
-
Gore SD et al (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66(12):6361–6369
-
(2006)
Cancer Res
, vol.66
, Issue.12
, pp. 6361-6369
-
-
Gore, S.D.1
-
173
-
-
68049120458
-
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes
-
COI: 1:CAS:528:DC%2BD1MXptl2gtrg%3D
-
Voso MT et al (2009) Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15(15):5002–5007
-
(2009)
Clin Cancer Res
, vol.15
, Issue.15
, pp. 5002-5007
-
-
Voso, M.T.1
-
174
-
-
70350506791
-
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
-
COI: 1:CAS:528:DC%2BD1MXht1eit7jL
-
Fandy TE et al (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114(13):2764–2773
-
(2009)
Blood
, vol.114
, Issue.13
, pp. 2764-2773
-
-
Fandy, T.E.1
-
175
-
-
84858685501
-
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
-
COI: 1:CAS:528:DC%2BC38XktVajsL8%3D
-
Gryder BE, Sodji QH, Oyelere Adegboyega K (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Futur Med Chem 4(4):505–524
-
(2012)
Futur Med Chem
, vol.4
, Issue.4
, pp. 505-524
-
-
Gryder, B.E.1
Sodji, Q.H.2
Oyelere Adegboyega, K.3
-
176
-
-
34547653955
-
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma
-
COI: 1:CAS:528:DC%2BD2sXotlGqurc%3D
-
Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R (2007) Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 13(15):4538–4546
-
(2007)
Clin Cancer Res
, vol.13
, Issue.15
, pp. 4538-4546
-
-
Kato, Y.1
Yoshimura, K.2
Shin, T.3
Verheul, H.4
Hammers, H.5
Sanni, T.B.6
Salumbides, B.C.7
Van Erp, K.8
Schulick, R.9
Pili, R.10
-
177
-
-
84856403025
-
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models
-
COI: 1:CAS:528:DC%2BC38Xitlyqs7c%3D
-
Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R (2012) Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7(1):e30815
-
(2012)
PLoS ONE
, vol.7
, Issue.1
-
-
Shen, L.1
Ciesielski, M.2
Ramakrishnan, S.3
Miles, K.M.4
Ellis, L.5
Sotomayor, P.6
Shrikant, P.7
Fenstermaker, R.8
Pili, R.9
-
178
-
-
84855340600
-
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
-
COI: 1:CAS:528:DC%2BC38XktFCnsQ%3D%3D
-
Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106(1):77–84
-
(2012)
Br J Cancer
, vol.106
, Issue.1
, pp. 77-84
-
-
Pili, R.1
Salumbides, B.2
Zhao, M.3
Altiok, S.4
Qian, D.5
Zwiebel, J.6
Carducci, M.A.7
Rudek, M.A.8
-
179
-
-
84902549532
-
Epigenetics in radiotherapy: where are we heading?
-
Smits KM, Melotte V, Niessen HEC, Dubois L, Oberije C, Troost EGC, Starmans MHW, Boutros PC, Vooijs M, van Engeland M, Lambin P (2014) Epigenetics in radiotherapy: where are we heading? Radiother Oncol 111(2):168–177
-
(2014)
Radiother Oncol
, vol.111
, Issue.2
, pp. 168-177
-
-
Smits, K.M.1
Melotte, V.2
Niessen, H.E.C.3
Dubois, L.4
Oberije, C.5
Troost, E.G.C.6
Starmans, M.H.W.7
Boutros, P.C.8
Vooijs, M.9
van Engeland, M.10
Lambin, P.11
-
180
-
-
84940109072
-
Targeting epigenetic processes in photodynamic therapy-induced anticancer immunity
-
Wachowska M, Muchowicz A, Golab J (2015) Targeting epigenetic processes in photodynamic therapy-induced anticancer immunity. Front Oncol 5:176
-
(2015)
Front Oncol
, vol.5
, pp. 176
-
-
Wachowska, M.1
Muchowicz, A.2
Golab, J.3
-
181
-
-
84921963991
-
Broad targeting of angiogenesis for cancer prevention and therapy
-
Wang Z et al (2015) Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 35(Suppl):S224–S243
-
(2015)
Semin Cancer Biol
, vol.35
, pp. S224-S243
-
-
Wang, Z.1
-
182
-
-
85017413453
-
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer: a review
-
Kuusk T, Grivas N, Bex A (2017) Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer: a review. Angiogenesis. doi:10.1007/s10456-017-9550-0
-
(2017)
Angiogenesis
-
-
Kuusk, T.1
Grivas, N.2
Bex, A.3
-
183
-
-
85016580058
-
-
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis
-
Ramjiawan RR, Griffioen AW, Duda DG (2017) Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. doi:10.1007/s10456-017-9552-y
-
(2017)
Duda DG
-
-
Ramjiawan, R.R.1
Griffioen, A.W.2
-
184
-
-
85016484861
-
The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future
-
Hamming LC, Slotman BJ, Verheul HMW, Thijssen V (2017) The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis. doi:10.1007/s10456-017-9546-9
-
(2017)
Angiogenesis
-
-
Hamming, L.C.1
Slotman, B.J.2
Verheul, H.M.W.3
Thijssen, V.4
-
185
-
-
0028060380
-
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
-
COI: 1:CAS:528:DyaK2cXmtVajtLk%3D
-
Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265(5178):1582–1584
-
(1994)
Science
, vol.265
, Issue.5178
, pp. 1582-1584
-
-
Dameron, K.M.1
Volpert, O.V.2
Tainsky, M.A.3
Bouck, N.4
-
186
-
-
0029562535
-
Inhibition of angiogenesis by thrombospondin-2
-
COI: 1:CAS:528:DyaK2MXpvVWhsLo%3D
-
Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF, Bouck N (1995) Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 217:326–332
-
(1995)
Biochem Biophys Res Commun
, vol.217
, pp. 326-332
-
-
Volpert, O.V.1
Tolsma, S.S.2
Pellerin, S.3
Feige, J.J.4
Chen, H.5
Mosher, D.F.6
Bouck, N.7
-
187
-
-
80155142474
-
Rapamycin passes the torch: a new generation of mTOR inhibitors
-
COI: 1:CAS:528:DC%2BC3MXhtlyis7vI
-
Benjamin D, Colombi M, Moroni C, Hall MN (2011) Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10(11):868–880
-
(2011)
Nat Rev Drug Discov
, vol.10
, Issue.11
, pp. 868-880
-
-
Benjamin, D.1
Colombi, M.2
Moroni, C.3
Hall, M.N.4
-
188
-
-
84884910068
-
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
-
COI: 1:CAS:528:DC%2BC3sXpvVynsL0%3D
-
Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Korner W, Jungwirth U, Mohr T, Keppler BK, Berger W (2013) The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer 49:3366–3375
-
(2013)
Eur J Cancer
, vol.49
, pp. 3366-3375
-
-
Heffeter, P.1
Atil, B.2
Kryeziu, K.3
Groza, D.4
Koellensperger, G.5
Korner, W.6
Jungwirth, U.7
Mohr, T.8
Keppler, B.K.9
Berger, W.10
-
189
-
-
85019799796
-
Phase I and II studies of the decitabine–genistein drug combination in advanced solid tumors
-
Kassouf E, Tehfe MA, Florescu M, Soulieres D, Lemieux B, Ayoub J-PM, Charpentier D, Yelle L, Daigneault L, Colin P, Momparler RL, Plante I, Lassonde G, Charbonneau MR, Raynal NJ-M, Blais N (2015) Phase I and II studies of the decitabine–genistein drug combination in advanced solid tumors. J Clin Oncol 33(15_suppl):e13556
-
(2015)
J Clin Oncol
, vol.33
-
-
Kassouf, E.1
Tehfe, M.A.2
Florescu, M.3
Soulieres, D.4
Lemieux, B.5
Ayoub, J.-P.M.6
Charpentier, D.7
Yelle, L.8
Daigneault, L.9
Colin, P.10
Momparler, R.L.11
Plante, I.12
Lassonde, G.13
Charbonneau, M.R.14
Raynal, N.J.-M.15
Blais, N.16
-
190
-
-
85044083341
-
Brain tumor trials collaborative bayesian adaptive Adaptive randomized phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102)
-
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Groves MD, Raizer JJ, Giglio P, Colman H, Peereboom DM, Walbert T, Avgeropoulos NG, Iwamoto FM, Chamberlain MC, Paleologos N, Gilbert MR (2015). Brain tumor trials collaborative bayesian adaptive Adaptive randomized phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). J Clin Oncol 33:1
-
(2015)
J Clin Oncol
, vol.33
, pp. 1
-
-
Puduvalli, V.K.1
Wu, J.2
Yuan, Y.3
Armstrong, T.S.4
Groves, M.D.5
Raizer, J.J.6
Giglio, P.7
Colman, H.8
Peereboom, D.M.9
Walbert, T.10
Avgeropoulos, N.G.11
Chamberlain, M.C.12
Paleologos, N.13
Gilbert, M.R.14
-
191
-
-
67349157687
-
Biomarkers for predicting clinical responses to HDAC inhibitors
-
COI: 1:CAS:528:DC%2BD1MXmsF2jt7o%3D
-
Stimson L, La Thangue NB (2009) Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 280(2):177–183
-
(2009)
Cancer Lett
, vol.280
, Issue.2
, pp. 177-183
-
-
Stimson, L.1
La Thangue, N.B.2
-
192
-
-
84896031643
-
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
-
COI: 1:CAS:528:DC%2BC2cXhtVOrtbY%3D
-
Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R (2014) Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495–501
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, Issue.3
, pp. 495-501
-
-
Wheler, J.J.1
Janku, F.2
Falchook, G.S.3
Jackson, T.L.4
Fu, S.5
Naing, A.6
Tsimberidou, A.M.7
Moulder, S.L.8
Hong, D.S.9
Yang, H.10
Piha-Paul, S.A.11
Atkins, J.T.12
Garcia-Manero, G.13
Kurzrock, R.14
-
193
-
-
0034326784
-
Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
-
COI: 1:CAS:528:DC%2BD3cXotV2lsL8%3D
-
Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R (2000) Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60(21):6039–6044
-
(2000)
Cancer Res
, vol.60
, Issue.21
, pp. 6039-6044
-
-
Plumb, J.A.1
Strathdee, G.2
Sludden, J.3
Kaye, S.B.4
Brown, R.5
-
194
-
-
85006437080
-
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms
-
Wang L, Li H, Ren Y, Zou S, Fang W, Jiang X, Jia L, Li M, Liu X, Yuan X, Chen G, Yang J, Wu C (2016) Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms. Cell Death Dis. doi:10.1038/cddis.2015.328
-
(2016)
Cell Death Dis
-
-
Wang, L.1
Li, H.2
Ren, Y.3
Zou, S.4
Fang, W.5
Jiang, X.6
Jia, L.7
Li, M.8
Liu, X.9
Yuan, X.10
Chen, G.11
Yang, J.12
Wu, C.13
-
196
-
-
33947242973
-
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation
-
COI: 1:CAS:528:DC%2BD2sXhvF2hsLg%3D
-
Yu C, Friday BB, Lai J-P, McCollum A, Atadja P, Roberts LR, Adjei AA (2007) Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 13(4):1140–1148
-
(2007)
Clin Cancer Res
, vol.13
, Issue.4
, pp. 1140-1148
-
-
Yu, C.1
Friday, B.B.2
Lai, J.-P.3
McCollum, A.4
Atadja, P.5
Roberts, L.R.6
Adjei, A.A.7
-
197
-
-
31544452076
-
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
-
COI: 1:CAS:528:DC%2BD28XlsFOquw%3D%3D
-
Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66(2):944–950
-
(2006)
Cancer Res
, vol.66
, Issue.2
, pp. 944-950
-
-
Witta, S.E.1
Gemmill, R.M.2
Hirsch, F.R.3
Coldren, C.D.4
Hedman, K.5
Ravdel, L.6
Helfrich, B.7
Dziadziuszko, R.8
Chan, D.C.9
Sugita, M.10
Chan, Z.11
Baron, A.12
Franklin, W.13
Drabkin, H.A.14
Girard, L.15
Gazdar, A.F.16
Minna, J.D.17
Bunn, P.A.18
-
198
-
-
33750614651
-
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis
-
COI: 1:CAS:528:DC%2BD28Xht1Glu7bM
-
Derksen PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J (2006) Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10(5):437–449
-
(2006)
Cancer Cell
, vol.10
, Issue.5
, pp. 437-449
-
-
Derksen, P.W.B.1
Liu, X.2
Saridin, F.3
van der Gulden, H.4
Zevenhoven, J.5
Evers, B.6
van Beijnum, J.R.7
Griffioen, A.W.8
Vink, J.9
Krimpenfort, P.10
Peterse, J.L.11
Cardiff, R.D.12
Berns, A.13
Jonkers, J.14
-
199
-
-
3242885067
-
Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo
-
COI: 1:CAS:528:DC%2BD2cXlvFehtLw%3D
-
Peinado H, Marin F, Cubillo E, Stark H-J, Fusenig N, Nieto MA, Cano A (2004) Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J Cell Sci 117(Pt 13):2827–2839
-
(2004)
J Cell Sci
, vol.117
, pp. 2827-2839
-
-
Peinado, H.1
Marin, F.2
Cubillo, E.3
Stark, H.-J.4
Fusenig, N.5
Nieto, M.A.6
Cano, A.7
-
200
-
-
84884995769
-
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
-
COI: 1:CAS:528:DC%2BC3sXhsV2mtb7J
-
Chen M-C, Chen C-H, Wang J-C, Tsai A-C, Liou J-P, Pan S-L, Teng C-M (2013) The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis 4:e810
-
(2013)
Cell Death Dis
, vol.4
-
-
Chen, M.-C.1
Chen, C.-H.2
Wang, J.-C.3
Tsai, A.-C.4
Liou, J.-P.5
Pan, S.-L.6
Teng, C.-M.7
-
201
-
-
84924875404
-
The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer
-
COI: 1:CAS:528:DC%2BC2cXhvF2jsLfF
-
Lee T-G, Jeong E-H, Kim SY, Kim H-R, Kim CH (2015) The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Int J Cancer 136(11):2717–2729
-
(2015)
Int J Cancer
, vol.136
, Issue.11
, pp. 2717-2729
-
-
Lee, T.-G.1
Jeong, E.-H.2
Kim, S.Y.3
Kim, H.-R.4
Kim, C.H.5
-
202
-
-
84864004796
-
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy
-
COI: 1:CAS:528:DC%2BC38XhtFCjtrbO
-
Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA, Hirsch FR (2012) Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 30(18):2248–2255
-
(2012)
J Clin Oncol
, vol.30
, Issue.18
, pp. 2248-2255
-
-
Witta, S.E.1
Jotte, R.M.2
Konduri, K.3
Neubauer, M.A.4
Spira, A.I.5
Ruxer, R.L.6
Varella-Garcia, M.7
Bunn, P.A.8
Hirsch, F.R.9
-
203
-
-
84896502954
-
A phase i, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors
-
COI: 1:CAS:528:DC%2BC2cXks1Ojt7c%3D
-
Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M, Kish JA, Kreahling J, Lush R, Neuger A, Tetteh L, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S (2014) A phase i, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res 20(6):1644–1655
-
(2014)
Clin Cancer Res
, vol.20
, Issue.6
, pp. 1644-1655
-
-
Gray, J.E.1
Haura, E.2
Chiappori, A.3
Tanvetyanon, T.4
Williams, C.C.5
Pinder-Schenck, M.6
Kish, J.A.7
Kreahling, J.8
Lush, R.9
Neuger, A.10
Tetteh, L.11
Akar, A.12
Zhao, X.13
Schell, M.J.14
Bepler, G.15
Altiok, S.16
-
204
-
-
77952673621
-
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates
-
COI: 1:CAS:528:DC%2BC3cXhtV2ntrzN
-
Loges S, Schmidt T, Carmeliet P (2010) Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1(1):12–25
-
(2010)
Genes Cancer
, vol.1
, Issue.1
, pp. 12-25
-
-
Loges, S.1
Schmidt, T.2
Carmeliet, P.3
-
205
-
-
84921963991
-
Broad targeting of angiogenesis for cancer prevention and therapy
-
Wang Z et al (2015) Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 35(Suppl):S224–S243
-
(2015)
Semin Cancer Biol
, vol.35
, pp. S224-S243
-
-
Wang, Z.1
-
206
-
-
84918767654
-
Discovery of a low order drug-cell response surface for applications in personalized medicine
-
Ding X, Liu W, Weiss A, Li Y, Wong I, Griffioen AW, van den Bergh H, Xu H, Nowak-Sliwinska P, Ho C-M (2014) Discovery of a low order drug-cell response surface for applications in personalized medicine. Phys Biol 11(6):65003
-
(2014)
Phys Biol
, vol.11
, Issue.6
, pp. 65003
-
-
Ding, X.1
Liu, W.2
Weiss, A.3
Li, Y.4
Wong, I.5
Griffioen, A.W.6
van den Bergh, H.7
Xu, H.8
Nowak-Sliwinska, P.9
Ho, C.-M.10
-
207
-
-
84979058861
-
Manipulating angiogenesis by targeting endothelial metabolism: hitting the engine rather than the drivers—a new perspective?
-
Treps L, Conradi L-C, Harjes U, Carmeliet P (2016) Manipulating angiogenesis by targeting endothelial metabolism: hitting the engine rather than the drivers—a new perspective? Pharmacol Rev 68(3):872–887
-
(2016)
Pharmacol Rev
, vol.68
, Issue.3
, pp. 872-887
-
-
Treps, L.1
Conradi, L.-C.2
Harjes, U.3
Carmeliet, P.4
-
208
-
-
84942795835
-
A streamlined search technology for identification of synergistic drug combinations
-
COI: 1:CAS:528:DC%2BC2MXhsFOku7bK
-
Weiss A, Berndsen RH, Ding X, Ho C-M, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P (2015) A streamlined search technology for identification of synergistic drug combinations. Sci Rep 5:14508
-
(2015)
Sci Rep
, vol.5
, pp. 14508
-
-
Weiss, A.1
Berndsen, R.H.2
Ding, X.3
Ho, C.-M.4
Dyson, P.J.5
van den Bergh, H.6
Griffioen, A.W.7
Nowak-Sliwinska, P.8
-
209
-
-
33847701595
-
Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma
-
COI: 1:CAS:528:DC%2BD2sXhvVWqtb8%3D
-
Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL (2007) Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 67(4):1716–1724
-
(2007)
Cancer Res
, vol.67
, Issue.4
, pp. 1716-1724
-
-
Yang, Q.1
Tian, Y.2
Liu, S.3
Zeine, R.4
Chlenski, A.5
Salwen, H.R.6
Henkin, J.7
Cohn, S.L.8
-
210
-
-
0035866341
-
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis
-
COI: 1:CAS:528:DC%2BD3MXhvVeltLo%3D
-
Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61(4):1477–1485
-
(2001)
Cancer Res
, vol.61
, Issue.4
, pp. 1477-1485
-
-
Pili, R.1
Kruszewski, M.P.2
Hager, B.W.3
Lantz, J.4
Carducci, M.A.5
-
211
-
-
77956652390
-
Resveratrol modulates angiogenesis through the GSK3β/β-catenin/TCF-dependent pathway in human endothelial cells
-
COI: 1:CAS:528:DC%2BC3cXhtFyitbjM
-
Wang H, Zhou H, Zou Y, Liu Q, Guo C, Gao G, Shao C, Gong Y (2010) Resveratrol modulates angiogenesis through the GSK3β/β-catenin/TCF-dependent pathway in human endothelial cells. Biochem Pharmacol 80(9):1386–1395
-
(2010)
Biochem Pharmacol
, vol.80
, Issue.9
, pp. 1386-1395
-
-
Wang, H.1
Zhou, H.2
Zou, Y.3
Liu, Q.4
Guo, C.5
Gao, G.6
Shao, C.7
Gong, Y.8
|